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This research focuses on assessing the effect of various formulation parameters on 
targeting human epidermal growth factor receptor-2 (HER2) specifically in breast cancer. Poly 
(D, L-lactide-co-glycolide) (PLGA) polymer, which is approved by FDA, was used to form 
nanoparticles (NPs) encapsulating docetaxel (DOC) as chemotherapy. HER2 antibody 
moieties, either whole IgG (TrAb) or single chain fragment variable (ScFv), were 
decorated on the PLGA NPs surface and evaluated in terms of their ability to target 
HER2 breast cancer cells. We observed the effects of these NPs against different cell 
lines (MCF-7 and SK-BR-3). Thus, ligand modified structurally concealed PLGA NPs 
could be a promising delivery tool for targeting HER2 breast tumor in vitro that 
improves the release of chemotherapy while reducing the systemic side effects. 
 
 A solvent evaporation procedure was adjusted to form NP formulations using 
both ester and carboxylic acid terminated PLGA. Incorporation of ligands (TrAb or 
ScFv) was conducted through chemical covalent conjugation processes by using 
different cross-linkers bis(sulfo-succinimidyl) (BS3) or N-hydroxysuccinimide esters 
(NHS) and 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). 
The size, zeta potential, polydispersity index, which were determined for the 
physicochemical characterizations. The physicochemical characterizations of 
formulations were executed to assess the effects of different ligands in vitro for drug 
targeting. Also, Fourier Transform Infrared (FTIR) was used to conform the covalent 
bond insertion between the linkers and ligands (TrAb or ScFv). DOC loading was 




quantification was performed by using the bicinchoninic acid (BCA) assay. Moreover, 
in vitro drug release profile was assessed. In vitro cellular targeting was examined by 
measuring the level of HER2 expression through Fluorescence-activated cell 
sorting (FACS) in two cell lines as well as western blot analysis. Cytotoxicity assay 
was performed in SK-BR-3 cell line for all the formulations.  
 
Modified PLGA NPs showed a mean diameter particle size below 400 nm with 
approximately neutral zeta potential; for example, ScFv-DOC-Ester PLGA NPs 
formulation size was 312 ± 8.769 nm, and their zeta potential was 0.024 ± 0.075 mV. 
The average size of the acidic PLGA TrAb-DOC NPs was 382.5 ± 21.5 nm, and their 
zeta potential was 0.045 ± 0.037 mV. DOC encapsulation efficiency reached up to 65% 
to 85% depending on the type of the NPs formulations, and the amount of anti-HER2 
attachment efficiency exceeded 40%. The cellular targeting of nanoparticles was 
studied using two cell lines MCF-7 (low HER2 expression) and SK-BR-3 (high HER2 
expression), and different levels of HER2 expression were evaluated. The significant 
reduction in the level of HER2 expression was observed for all modified NPs 
formulations in HER2 overexpressed SK-BR-3 cells.  
 
Overall, in vitro targeting further demonstrated that modified NPs accumulated 
DOC in tumor cell line more efficiently than conventional medication. The TrAb 
conjugated to DOC modified NPs formulations were able to increase the HER2 
targeting for DOC compared to ScFv modified NPs. In SK-BR-3 cells, the cytotoxicity 




slow release of DOC from the modified NPs. This system has the potential of 
improving the targeting and the release of chemotherapeutic drugs into the tumor cells 
while reducing the side effects caused by affecting healthy tissues. 
 
Our data demonstrated that the high affinity for anti-HER2 modified PLGA 
NPs formulations to efficiently and explicitly target DOC to the HER2 overexpressing 
cancer cells can be  exploited as a potential strategy for chemotherapeutic drug delivery 
system for HER2 overexpressing breast cancers. Thus, ligand modified structurally 
concealed PLGA NPs could be a promising delivery tool for targeting HER2 breast 
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Various types of cancer overexpress a number of proteins called tumor 
antigens. One of which is human epidermal growth factor receptor-2 (HER2) that is 
present in 25–30% of breast cancer types in women (Antonio C. Wolff, Mitchell 
Dowsett, Edith A. Perez, & Marc van de Vijver, 2007). The HER2 antigen is one of the 
most useful biomarkers in early stages of diagnosis. In addition, HER2 antigen can be 
useful in targeted therapies (Choi et al., 2015).  
Classical chemotherapeutic agents used in treating cancer show many 
limitations and severe side effects due to lack of selectivity. This lack of selectivity 
means that chemotherapy works on both cancer cells as well as healthy cells (Kamaly, 
Xiao, Valencia, Radovic-Moreno, & Farokhzad, 2012). Recently, many research 
studies have been focusing on using nanotechnology to overcome chemotherapeutic 
limitations. For instance, enhancing the selectivity of cancerous cells using targeting 
ligands on nanoparticles would improve drug efficacies in cancerous cells and 
minimize the effect on healthy cells.  
Recently, the humanized monoclonal antibody such as trastuzumab 
(Herceptin®) is approved by the FDA for treating HER2 overexpressed breast cancer 
patients. Trastuzumab could selectively target cancer cells that overexpress HER2 
receptors. However, using trastuzumab as monotherapy showed low response as well 
as low survival rate. Therefore, the combination of trastuzumab with the first-line 
chemotherapy clinically has indicated significant synergistic effect in latest years (B. 




One of the most effective chemotherapeutic drugs for treating HER2 breast 
cancer is docetaxel as one of the most effective chemotherapy, but patients typically 
suffer from severe adverse effects (such as leukopenia, thrombocytopenia, and 
alopecia, etc.) (Fauzee et al., 2012). Therefore, combining both trastuzumab and 
docetaxel in nano-delivery systems for targeting HER2-positive breast cancer could be 
a promising approach. Application of a targeted drug delivery system against a specific 
tumor antigen would enhance the concentration of docetaxel in the defective cells, 
leading to improved therapeutic effect and reduce side effects. The modified drug 
delivery system could ultimately minimize the systemic exposure of the 
chemotherapeutic agent (Nobs, Buchegger, Gurny, & Allemann, 2004). 
 This research will propose the formulation of the PLGA (Poly (D, L-lactide-co-
glycolide) NPs that encapsulate the chemotherapeutic agent (docetaxel); and ultimately 
conjugate with either monoclonal Ab (trastuzumab, which binds to HER2) or ScFv 
(Single-Chain Fragment Variable) IgG anti-HER2 on the surface of NPs. The rationale 
behind this research is to improve the potential for targeting and releasing docetaxel to 
cancerous cells overexpressing the HER2 receptor, subsequently leading to enhancing 










2. LITERATURE REVIEW 
2.1. Breast Cancer Overview 
Cancer is considered the second cause of death worldwide after Cardiovascular 
diseases. Lung, breast, colorectal, prostate, and stomach are the most frequent areas 
of tumor growth and spread  (Ferlay et al., 2015). Breast cancer is the most 
common type of cancer affecting women worldwide leading to a higher rate of 
mortality among females and is the second most common recurrent type of cancer 
(Jemal et al., 2011; Torre et al., 2015). Over 10 million cases of cancer are 
diagnosed each year globally (Misra, Acharya, & Sahoo, 2010). According to the 
Canadian Cancer Society’s Steering Committee on Cancer Statistics, the occurrence 
of breast cancer is estimated to be approximately 130.1 cases per 100,000 women, 
and 90% of deaths related to cancer cases are due to metastatic growth ("Canadian 
Cancer Statistics ", 2017) 
Genetic damage or alteration causes cancerous diseases that lead to abnormal 
proliferation and activities. Cancerous cells start competing for more nutrients to keep 
up with the rapid proliferation and uncontrollable cell division (Brannon-Peppas & 
Blanchette, 2004). The second most common type of cancer leading to death are the 
breast tumors (McGuire, 2016; Tarver, 2012).  Breast cancer is classified into four 
subtypes according to biomarker and gene expression profiles: 
(1) Luminal A: affects around 50–60% of breast cancer patients. This subtype 
express an estrogen receptor (ER). The expression of progesterone receptor (PR) 
could be positive or negative, and a low level of Ki67 protein with no expression 




(2) Luminal B: incidence is almost 10–20%. ER-positive, high level of Ki67, and 
HER2-negative are the frequent pattern of biomarker expression; however, in a 
few cases this subtype can be HER2 positive and ER negative, which is a very 
aggressive type of breast tumor with a high rate of proliferation. This subtype 
commonly metastasizes in bone. 
(3) Basal-like or triple-negative cancer has a high expression of proliferation genes, 
but with the absence of HER2, ER, and PR receptors. This subtype is usually 
identified in African American women and commonly metastasizes to lung and 
nervous system tissues (Barnato & Gradishar, 2015). 
(4) HER2 breast cancer encompasses around 25-30% of the cancer cases (Scheuer 
et al., 2009). HER2 amplification means that patients get proliferation in 
chromosome 17(17q12), causing a greater production of the proto-oncogene 
leading to expression of more HER2 receptors on the cell surface. Also, HER2 
is a receptor of tyrosine kinase (ErbB2). Therefore, more epidermal growth 
factor (EGF) will bind to the cells and cause enhanced proliferation. In addition 
to HER2 cancer, 40% of the patients get a P53 mutation. HER2 tumors have a 
higher rate of local recurrence and commonly metastasize in the brain, liver, and 
lungs. In the past, HER2 tumors have had a poor prognosis and survival rate; 
however, after producing a targeted medication for HER2 (trastuzumab), there 
has been an improvement in survival rates for early-stage diagnosis (Barnato & 




2.2. Breast Cancer Treatment 
Conventional treatment of cancer includes surgery alongside radiotherapy for 
localized primary or secondary tumors. However, such treatments are ineffective for 
metastatic cancer (Toraya-Brown et al., 2013). Additionally, chemotherapeutic agents 
are considered the most efficient way to treat cancer, but they have high adverse effects 
due to their lack of specificity, which destroys healthy cells along with cancer cells 
(Hamdy, Haddadi, Hung, & Lavasanifar, 2011). Common side effects of chemotherapy 
include nausea, vomiting, alopecia, and neutropenia (Figure 1). Chemotherapy is also 
limited due to poor stability and physiochemical properties. The most common 
drawback of anticancer drugs is poor bioavailability due to their high molecular weight 
and multiple drug resistance (Shapira, Livney, Broxterman, & Assaraf, 2011). Specific 
targeted drug delivery can overcome the limitations of chemotherapeutic agents. 
Therefore, many researchers are focusing on nanotechnology to carry cytotoxic drugs 
to the specific target tumor site (Gillet & Gottesman, 2010; C.-M. J. H. a. L. Zhang, 
2009 ). 
Today hundreds of chemotherapeutic agents are available for cancer treatment, 
and cancer patients generally take a combination of two or three chemotherapeutic 
agents. One of the most primary chemotherapeutic agent that has been used for treating 
breast cancer is 5-Fluorouracil (antimetabolites), which works on inhibiting the cell 
cycle by preventing the chromosomes to cope (Longley, Harkin, & Johnston, 2003). 
Another class of chemotherapeutic agents is antitumor antibiotic (doxorubicin and 
daunorubicin) which is widely used for breast cancer. Doxorubicin is main mechanism 




Pinedo, Schuurhuis, & Joenje, 1990). Finally, the mitotic inhibitor chemotherapeutic 
agents  which is paclitaxel and docetaxel. Paclitaxel (Taxol ®), was a 
chemotherapeutic agent, that was isolated from the bark of Taxus brevifolia in 1990, 
and docetaxel (Taxotere ®), which is a semisynthetic analogue to paclitaxel was first 
used in 1995. The two taxanes are used commonly for breast cancer patients as one of 
the first line chemotherapy  (Tsai, 2001).   
 










Docetaxel (DOC) is a microtubule inhibitor anticancer agent extensively used 
to treat breast cancer (Figure 2). It functions in the G2/M phase of the cell cycle by 
binding to β-tubulin to inhibit depolymerization of the microtubules. The microtubule 
is one of the most important structures in the cytoplasm of a eukaryotic cell, as it acts 
intra-cellularly as a cytoskeleton and is essential for movement within the cell; for 
example, moving the chromosomes during cell mitosis. Docetaxel suspends cells in 
metaphase due to the desegregation of the chromosome which leads to cell death 
(Fumoleau, Seidman, Trudeau, Chevallier, & Ten Bokkel Huinink, 1997; Youm, Yang, 
Murowchick, & Youan, 2011).  
From a pharmacokinetic perspective, DOC has a high volume of distribution 
due to high binding affinity with tissues. However, it does not cross the blood-brain 
barrier as it is a substrate for efflux transporters. Docetaxel is metabolized mainly by 
liver cytochrome P450. As with other chemotherapeutic agents, DOC has many side 
effects, including nausea, diarrhea, hair loss, weakness, infection, peripheral 












The ideal approach to deliver cytotoxic drugs to tumor cells with minimal effect on 
healthy cells is by active targeting, which could minimize the systemic side effects and 
enhance the therapeutic outcome. Aptamers, antigen-antibody interaction, and ligand 
receptors are examples of molecules specific for different targeting moieties on the 
cells that are able to recognize and actively target the tumor cells (Nishioka & Yoshino, 
2001). For instance, Farokhzad et al., produced PLGA-PEG nanoparticles that 
encapsulated docetaxel and conjugated with A10 2-flouoropyrimidine RNA aptamers 
to target prostate cancer (prostate-specific membrane antgine). In vitro, there was a 
significant cellular toxicity and full tumor reduction in vivo (Farokhzad et al., 2006).  




pancreatic cancer cell (Frasco, Almeida, Santos-Silva, Pereira Mdo, & Coelho, 2015). 
In HER2 breast tumors, HER2 receptors would be overexpressed 100 times more on 
the surface of tumor cells than normal cells. This could also occur in some types of 
lung and prostate cancers (Salomon, 1995). The human body treats drug delivery 
formulations as a foreign agent, so it could be removed by the liver and spleen from 
circulation via the reticuloendothelial system (Davis, Chen, & Shin, 2008; Grislain, 
1983).  
Producing targeted NPs formulation requires ligands attached on the surface to bind 
them with the tumor cell. There are different cross-linking agents used to conjugate the 
ligand to NPs (Koopaei et al., 2011). Firstly, bis-sulfosuccinimidyl suberate (BS3) is a 
homobifunctional spacer that has been used as a cross-linker to develop covalent amide 
bond between Ab and NPs (Thamake, Raut, Ranjan, Gryczynski, & Vishwanatha, 
2011). The mechanism of action is in one step without any modification; it forms a 
covalent amide bond between a carboxylic group of BS3 and Lysine of Ab by releasing 
a sulpho-NHS group at the end of both sides of the spacer. This conjugation can be 
carried out at physiological pH which decreases the chances of degradation of the 
targeting moiety including the Ab. However, undesirable polymerization or self-
conjugation of Ab can be occurred (Brufsky, 2010).  
The second group of cross-linker agents is NHS (N-Hydroxysuccinimide 
Esters)/EDC (1-ethyl-3- (3-dimethylaminopropyl), which is a heterobifunctional cross-
linker containing an amine-reactive succinimidyl ester (NHS) at one end and a 
sulfhydryl-reactive group at the other end. It is a commonly used strategy to crosslink 




(carbodiimide chemistry) to form an amide linkage. This is a two-step conjugation, 
which would minimize antibody-to-antibody linkages. NHS esters are reactive groups 
formed by carbodiimide-activation of carboxylate molecules. 
Polymeric NPs have specific ligands that can carry docetaxel to tumor cells without 
affecting other cells. Also, many studies have shown that a combination of DOC with 
other medications (trastuzumab) improves the prognosis of administration and reduces 
side effects.  
 
 
2.4. HER2 Receptor 
Human epidermal growth factor receptor (HER) has four (homologous) subtypes: 
HER1, HER2, HER3, and HER4. HER2 is also known as receptor tyrosine-protein 
kinase (erbB-2, CD340, Proto-oncogene Neu, ERBB2). Normally, HER2 has low 
expression in the healthy adult human body. It exists as either a heterodimer or 
homodimer; therefore, it has two extracellular domains as well as intracellular, but 
HER2 is the only one in this family that does not have an identifiable ligand for the 
extracellular domain (Mitri, Constantine, & O'Regan, 2012). Moreover, HER2 has an 
N-terminal cysteine in the extracellular domain, a single #-helix trans-membrane 
lipophilic, and an intracellular tyrosine kinase in the cytoplasm (Tai et al., 2010). The 
binding of epidermal growth factor (EGF) to HER2 receptors will auto-
phosphorylation the receptor. Then, auto-phosphorylated HER2 will activate the 
phosphorylation residues intracellular and regulate cellular processes: a. MAPK/ ERK 
pathway (mitogen-activated protein kinase [MAPK] extracellular signal-regulated 




2006; Koutras1 & Evans2, 2008). The pathway outputs promote cells to move on in the 
cell cycle from the interphase to the G1 phase by increasing the affinity of the RNA-
polymerase to the promoter to initiate gene transcription (Figure 3) (Scheuer et al., 
2009). As a result, amplification of the HER2 receptor will lead to uncontrollable cell 
proliferation. The distinctive antigen (HER2) exposed on the cells’ surface makes it 
ideal for antibodies to target without affecting other cells (Arruebo, Valladares, & 
González-Fernández, 2009). Similar monoclonal antibodies work against particular 
antigens (trastuzumab), so they have minimum side effects. Therefore, it has been an 










Trastuzumab (brand name Herceptin® from Genentech) is an IgG1 humanized 
monoclonal Ab that has been approved mainly for treating HER2 breast cancer as well 
as other HER2 tumors such as gastric cancer. The average molecular weight of 
trastuzumab is 150 kDa, and the route of administration is via intravenous infusion. 
Trastuzumab’s effectiveness in improving the survival rate as monotherapy is found to 
be around 30% for HER2 breast cancer (Bang, Van Cutsem, Feyereislova, & 




treatment has been recommended as a combination of trastuzumab with other 
chemotherapy medications such as capecitabine, 5-fluorouracil, and cisplatin for 
metastatic gastric cancer (Bang, Van Cutsem, Feyereislova, Chung, et al., 2010). In 
HER2 breast cancer, most of the studies suggest combining trastuzumab with 
paclitaxel, docetaxel, or aromatase inhibitors for post-menopausal women (Boekhout, 
Beijnen, & Schellens, 2011). The combination of trastuzumab plus chemotherapy 
(Taxanes mainly) has demonstrated disease-free and overall survival advantages for 
patients in early stages of HER2 breast cancer. Table 1 provides a summary of the 
chemotherapy agents (DOC) used in combination with trastuzumab in phase III clinical 
trials (adapted from Komen, 2015). Furthermore, Genentech received approval from 
the FDA on April of 2013 to use a combination of trastuzumab and Taxane as an 
adjuvant therapy for patients with HER2 cancer due to the positive outcome. Although 
the combination reduces dysfunction of left ventricular ejection velocity, which is the 
primary toxicity for trastuzumab,  in most cases this ventricular dysfunction is found to 
be reversible (Boekhout et al., 2011). Also, some patients develop resistance from 











Table 1. Summary of different chemotherapy agents used in combination with trastuzumab in 
phase III clinical trials (adapted from Komen, 2015). 
N/A = Not available 
* Estimated survival at 15 months of follow-up. 





Trastuzumab (Fab region) acts by binding to the C-terminal at the extracellular 
domain of the HER2 receptor, and the mechanism of action is not yet fully understood. 
(see Figure 4) However, trastuzumab Ab blocks HER2 dimerization 
(homodimerization with itself and heterodimerization with other HERs) that 
deactivates the intracellular signaling pathways (MAPK/ERK and PI3K) (Spector & 
Blackwell, 2009). Also, trastuzumab stimulate the immune system by producing 
antibody-dependent cellular cytotoxicity (ADCC) against HER2 tumor cells which 
decompose the cells. In addition, cell apoptosis will happen due to the increase in p27 
level because of the suppression of the G1 phase of the cell cycle (Scheuer et al., 
2009). Figure 4 illustrates the trastuzumab mechanism.  
 
 




Trastuzumab with chemotherapy 
(docetaxel) 69% 62%
* 
Trastuzumab with chemotherapy 
(docetaxel) 59% 88% 
Trastuzumab with chemotherapy 
(docetaxel) 73% 89% 
Trastuzumab with chemotherapy 
(docetaxel and carboplatin) 73% 91% 
Trastuzumab with chemotherapy 










Many studies have suggested the benefits of using trastuzumab as a targeted 
ligand, for instance, loading paclitaxel in poly(lactic-co-glycolic acid) or polyethylene 
glycol (Ma et al., 2015). Table 2 shows how trastuzumab has been used as a surface 
decorating ligand in different nano-systems to target HER2 cancer.
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Table 2. Different polymeric NPs used to target HER2 cancer cells.  






Loaded Drug Cell Pathology/Target Reference 
Polylactide 
(PLA)  






















Trastuzumab  Paclitaxel 





















































(Ma et al., 
2015) 
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2.4.2. Fragment Antibody 
Some studies have used fragment Ab (ScFv, Single-Chain Fragment Variable) 
to target medications instead of the whole Ab. ScFv consists only the antigen-binding 
unit of the immunoglobulin. This may overcome some challenges of monoclonal 
antibodies especially regarding its large size; in addition, it enhances the rate of tumor 
uptake as well as the specification of targeting (Ahmad et al., 2012). Table 3 
summarizes the application of fragment Ab to target the formulations for imaging and 
treatment purposes. For example, Kanazaki et al. (2015) lab used ScFv anti-HER2 to 
target iron oxide NPs for tumor imaging.  
 
 
Table 3. Different studies using fragment Ab for targeting drug delivery systems.  








Iron Oxide NPs Anti-HER2 ScFv Photoacoustic tumor 
imaging  
(Kanazaki et al., 2015) 
Gallium-68 
 
Anti-HER2 ScFv Evaluate HER2 state 
by positron emission 
tomography (PET) 
imaging 






Nanotechnology is considered a novel technique in the pharmaceutical field for 
treatment and disease diagnosis, especially in oncotherapy. There are different 
structures and compositions of nanoparticles, which produce various types of 
nanosystems, such as liposomes, gold nanoparticles, and polymeric nanoparticles, etc. 
Different types of nanosystems are used in imaging such as magnetic iron oxide NPs to 
target the luteinizing hormone-releasing hormone (LHRHR) tumor receptor and in 
targeting different medications to different organs. (Yingna Ha, Linhua Zhang, 
Dunwan Zhu, & Song, 2014), and thiolated trastuzumab in human serum albumin NPs 
to target HER2 breast cancer cells (Steinhauser, Spankuch, Strebhardt, & Langer, 
2006). 
Nanoparticles could target and deliver therapeutic agents with minimal side 
effects; and can exhibit superior pharmacokinetic properties and therapeutic outcomes 
over the conventional forms of the treatments. Also, nanoparticles have the ability to 
overcome drug resistance in some cases because of the differences in physiochemical 
characteristics such as the large surfaces, which enhance the nanoparticles ability to 
bind, adsorb, or carry therapeutic agents (De Jong & Borm, 2008; Valladares, & 
González-Fernández, 2009). In addition, change in nanoparticle surface charge helps to 
avoid endosome and lysosome degradation so that therapeutic agents can be delivered 
to the cell cytoplasm. Nanoparticles require biodegradable materials for transporting 
and releasing the therapeutic agents in the affected organs. Moreover, selecting the 
place of release to achieve the high level of drug administration can be passive by 
depending on the enhanced permeability and retention effect (EPR) in cancer site. On 
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the other hand, conjugating nanoparticles with the ligands, such as antibodies, 
aptamers, and peptides, will target the tumor organ actively. Different ligands can be 
conjugated on the surface of nanoparticles to bind to a specific receptor that is 
overexpressed on cancer cells. This would decrease the toxicity effect in normal cells 
and improve the selectivity for tumor cells while defeating them (De Jong & Borm, 
2008). Huang et al. (2014) have also used protamine to target and overcome drug 
resistance to doxorubicin-loaded PLGA NPs to treat breast tumors. Consequently, 
nanomedicine could be justified as an optimal approach to deliver chemotherapeutic 
agents due to the improvements in its pharmacological properties and cytotoxic effects. 
However, targeting nanoparticles in vivo has been challenging because the 
majority of NP formulations will be taken up through phagocytosis. Adding 
polyethylene glycol (PEG) on the surface can enhance the half-life and prevent 
phagocytosis. Besides, NP size is a critical issue; small particle size (10-30 nm) will be 
eliminated by renal excretion, and larger size (>400 nm) will be engulfed by 
macrophages (Joanna Rejman, 2004). 
 
2.4.3.1. PLGA Nanoparticles 
Poly (lactic-co-glycolic acid), or PLGA, is the only synthetic biodegradable 
polymer that has been approved by the Food and Drug Administration (FDA). It is 
composed of lactic and glycolic acids, and it is degraded via a bulk erosion mechanism. 
The degradation rate depends on its crystalline-amorphous structure, hydrophilicity, 
and molecular weight; therefore, a higher proportion of glycolic acid increases 
hydrophilicity and degradation (see Figure 5) (Hamdy et al., 2011). Also, PLGA can 
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have different terminal groups such as free carboxylic acid (COOH), which can result 
in acidity or an esterified terminal. The terminal group can impact the therapeutic agent 
encapsulation efficiency, degradation, and stability of the formulation (Jahan & 
Haddadi, 2015). PLGA nanoparticles have been used in many drug delivery systems 
due to enhanced pharmacodynamic and pharmacokinetic profiles of therapeutic agents. 
There are many methods to prepare PLGA NPs, such as emulsification solvent 
evaporation, precipitation, polymerization, self-assembly, and salting out. The goal of 
NP application and the type of therapeutic agents are the main criteria for choosing the 




Figure 5. The chemical structure of PLGA. 
 
 
Targeting NPs can be divided into two subtypes: first passive targeting which 
depends on the enhancement of the permeability retention effect. Second, active 
targeting by conjugating the nanoparticles with a ligand or Ab that will bind to a 
 
 21 
particular receptor. Conjugating nanoparticles with peptides, nucleotide aptamers, or 
antibodies enhance particle recognition and accumulation in tumor areas (De Jong & 
Borm, 2008; Valladares, & González-Fernández, 2009). In HER2 breast cancer, using 
a monoclonal Ab such as trastuzumab enhances the targeting properties. An Ab 
fragment can also be used that will maintain its specificity and improve its ability to 
penetrate different types of tissues. Table 4 shows examples of various studies that 
have used different ligands or a fragment of Ab to target NPs. It has been reported that 
the penetration into a solid tumor takes about 54 hours for an entire IgG, whereas a Fab 
fragment takes only 16 hours (Arruebo et al., 2009).  
There are many factors to be considered preparing nanoparticles, such as the 
release and incorporation of therapeutic agents, biocompatibility, formulation stability, 
distribution, functionality, targeting, and adverse effects. One of the biggest challenges 
of modified NPs is losing the functional activity of the therapeutic agents and ligands 
when it encapsulated in NPs. Also, many of the materials used in preparing NPs has a 
toxicity effect. 
One of the most significant problems of nanoparticle preparation is 
reticuloendothelial phagocytosis system which recognizes the NPs by the liver and 
spleen (for large NPs) (De Jong & Borm, 2008). Therefore, NPs size is critical to 
prevent the NPs clearance until it reaches the defected organ because the kidney will 
filter small particles. Also, surface charge (ZP) of NPs affect the cellular uptake. 
Neutral ZP particle will have longer blood circulation with better ability to target cells. 
Whereas, the extreme positive or negative ZP will have high phagocytosis rate. 
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Agent Purpose of Study Output Linker Ligand Reference 
Superparamagnetic 





- Targeting magnetic 
resonance imaging 
for cancer  
Enhance the 
selectivity for tumor 




































Protamine (H. Wang et 
al., 2014) 




- Direct targeting of 
HER2 breast tumor 
cells 
Efficient uptake for 
trastuzumab by which  





































(Y. Wang et 
al., 2013) 
 






Agent Purpose of Study Output Linker Ligand Reference 
Selenium 
nanoparticles  
Doxorubicin Enhanced cellular 
uptake and efficacy 




cancer cells in vitro. 
In vivo showed 
synergistic efficacy 








acid block copolymers 












 (J. Huang et 
al., 2014) 
Nanoparticles of poly 
(ethylene glycol)-b-







breast cancer that 
overexpresses c-Myc 
Inhibit tumor growth 
in vitro.  
No toxicity or 
immunogenicity 
effect for the 
formulation in vivo. 
 
 
- - (Liu et al., 
2014) 
Copolymer of poly 









resistance by cancer 
stem cells and 
improve the response 
for chemotherapy  
 
Combination of 
decitabine NP and 
doxorubicin NP is 
more efficient. 
 
- - (Li et al., 
2015) 
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targeting and gene 
therapy 
Enhance targeting the 
cancer cells. 
Enhanced NP uptake 


















Docetaxel Target chemotherapy 















et al., 2014) 
Gold nanoparticles,  Doxorubicin Targeting 
doxorubicin to breast 
cancer 









(Banu et al., 
2015) 
Folic acid-PEG, dual 
amino acid-modified 
chitosan complexed  
DNA Target cancer cells 
and enhance anti-
tumor efficacy  
 
Enhance efficacy of 
the delivery system  
 









Doxorubicin Anti-cancer activity, 
introduces better 
efficacy and lower 
toxicity for treatment 
Targeted cancer cells. 
Enhanced anticancer 
activity. 
Reduced side effects. 
Positive result in 
vitro only. 




yay et al., 
2012) 
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Research in future 
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complexes, for two 
types of breast cancer 
cells: 
-The mucin 1 
(MUC1) and 
- Human epidermal 
growth factor 
receptor 2 (HER2) 
Highly sensitive and 
selective. 
However, it is needed 
to overcome: 
instability of nucleic 
acids in the blood, the 
short half-life of 
silica in circulation 
and the degradation 










(Jo, Her, & 
Ban, 2015) 
 




3. PURPOSE OF PROJECT 
3.1. Purpose 
The study aims to formulate ideal PLGA NPs that can encapsulate docetaxel 
and allow its surface to be decorated with trastuzumab or fragment ScFv IgG anti-
HER2 to target HER2 expressing breast cancer cells in vitro. 
 
3.2. Rationale  
The rationale of my research is to develop a targeted therapy using 
nanoparticles that if successful can overcome the adverse effects of conventional 
chemotherapy for cancer patients involving administration of nonspecific treatment 
with a broad-spectrum approach. Various chemotherapy treatments have poor 
characteristics, such as a short half-life, instability and systemic toxicities. 
Nanotechnology research focuses on overcoming these challenges by targeting drug 
delivery systems to enhance the therapeutic efficacy for anticancer drugs as well as the 
early detection of tumors by imaging. This study takes advantage of polymeric NPs to 




The hypothesis is that the modification of the surface of PLGA NPs carrying 
docetaxel by a monoclonal Ab (trastuzumab) or fragment ScFv IgG anti-HER2 will 
preferentially target the HER2 receptor on the membrane of tumor cells and improve 




Docetaxel as a chemotherapeutic agent can be carried by polymeric PLGA 
nanoparticles modified with trastuzumab (monoclonal Ab) or fragment ScFv IgG anti-
HER2 to target mainly breast cancer cells that overexpress HER2 receptors. This will 
lead to target the drug delivery systems which would avoid the systemic distribution 
(toxicity) of chemotherapy to the body. In this regard, the following specific objectives 
have been considered: 
1. To develop PLGA polymeric NPs loaded with docetaxel and decorated with a humanized 
monoclonal Ab (trastuzumab) or fragment ScFv IgG anti-HER2 on the NPs’ surface by 
using two different cross-linking agents BS3 (suberic acid bis [3-sulfo-N-
hydroxysuccinimide ester] sodium salt) and NHS/EDC (N-hydroxysuccinimide)/(1-ethyl-
3-[3 dimethylaminopropyl]-carbodiimide) 
2. To study the physicochemical characterization of modified nanoparticles in terms of: 
a) Size, zeta potential, polydispersity index, and surface imaging  
b) Quantification of docetaxel loading and encapsulation efficiency  
c) Quantification of Ab attachment on PLGA NPs that encapsulated docetaxel 
d) In vitro docetaxel release for modified PLGA nanoparticles  
3. To evaluate cell viability and IC50 in SK-BR-3 cell line 
4. To investigate the in vitro tumor cell targeting by evaluation of HER2 receptor 
expression in MCF-7 (moderately expressed HER 2 receptor) and SK-BR-3 




4. MATERIALS & METHODS 
4.1. Materials 
Both ester- and COOH-terminated PLGA were purchased from Birmingham 
Polymers, (LA, USA) and the inherent viscosity of both polymers was 0.15-0.25 dl/g. 
Docetaxel was purchased from LC Laboratories. Trastuzumab (Herceptin ®) was from 
Genentech. Anti-HER2 fragment (ScFv) was purchased from Creative Biolabs. 
Polyvinyl alcohol (PVA), bis(sulfo-succinimidyl) suberate (BS3), 0.25% Trypsin-
EDTA solution and Fetal Bovine Serum were purchased from Sigma-Aldrich Co., (St 
Louis, USA). Other reagents used were N-hydroxysuccinimide esters (sulfo-NHS), 1-
ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), bicinchoninic 
acid (BCA) protein assay kit, and dialysis cassettes 3.5 k MWCO (66330) from 
Thermo Fisher Scientific (Waltham, USA). All cell lines (MCF-7, and SK-BR-3) were 
from American Type Culture Collection (ATCC) (Manassas, USA). Solvents like 
chloroform and ethyl acetate were of analytical grade. Also, MTS assay kit (CellTiter 
96 AQueous One Solution Cell Proliferation Assay) was purchased from Promega. 
Finally, the Purified Mouse Anti-Human ErbB2 was secured from Biosciences and the 
Goat Anti-mouse IgG was obtained from BioRad.  
 
4.2. Preparation of NPs 
Two techniques of NPs preparation were carried out to prepare modified drug 





Table 5. Variable parameters considered in NPs drug delivery systems. 
Polymer PLGA • Carboxylic acid- (COOH) terminal 
• Ester-terminal 
Organic solvent • Chloroform  
• Ethyl acetate 
Cross-linkers • NHS-EDC 
• BS3 
PVA • 2.2% 
Cryoprotectant • Sucrose 
 
 
4.2.1. Solvent Evaporation Method   
The solvent evaporation technique was used for preparing an oil-in-water (o/w) 
emulsion to encapsulate docetaxel in PLGA NPs. The oil phase was composed of an 
organic solvent (chloroform or ethyl acetate depending on the PLGA terminal), 3% w/v 
docetaxel, and 6.5 % w/v of PLGA. Then 2.2% w/v PVA (polyvinyl alcohol) was 
added as a water phase followed by sonication. Subsequently, the emulsion was left to 
allow evaporation of the organic solvent (see Figure 6). The NP formulation was 
washed to remove the residual PVA. Then the NPs were freeze-dried (FD) and stored 






Figure 6. The scheme shows the solvent evaporation technique for NPs preparation. 
 
 
4.2.2. Precipitation Method 
The NanoAssemblr Benchtop (Vancouver, Canada) machine was used to mix 
the organic and water phases; the flow rate ratio was selected to be 1:1 according to the 
instrument manual. Different concentrations of PLGA (5%, 6.5%, and 10% w/v) and 
docetaxel (3%, 5%, and 10% w/v) were used and dissolved in acetone as the oil phase, 
and 2% of PVA was utilized as the aqueous phase.   
 
4.2.3. Trastuzumab and Fragment ScFv IgG Conjugation 
A covalent amide bond was created to attach trastuzumab and the fragment 
ScFv IgG to PLGA-DOC NPs by BS3 (suberic acid bis [3-sulfo-N-
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hydroxysuccinimide ester] sodium salt) or NHS (N-Hydroxysuccinimide esters) /EDC 
(1-ethyl-3- [3-dimethylaminopropyl] carbodiimide hydrochloride) as linkers. 
 
4.2.3.1. Trastuzumab extraction from Herceptin 
PBS buffer (pH 7.4) was used to dissolve Herceptin in a 2:1 ratio, followed by 
centrifugation (AllegraTM 25R, Beckman Coulter) in filtration tube, for 10 minutes at 
4oC and 4,100 rpm. After that, the concentration body will be reverted to the filtration 
tube and centrifuged again at 3,000 rpm for 5 minutes. At the final process, the 
concentrated filtrate will be collected, which will contain the trastuzumab without other 
excipients.  
 
4.2.3.2. Using BS3 
BS3 at 0.05 % w/v was dissolved in PVA 2.2% w/v while preparing NPs to carry 
docetaxel. Ester-terminated PLGA-DOC-BS3 in PBS (pH =7.4) was added to 
trastuzumab or ScFv IgG and stirred at room temperature for 1 hour followed by 
washing steps. The NPs were freeze-dried and stored at -20° C for future studies. 
 
4.2.3.3. Using NHS/EDC 
NHS/EDC was dissolved in PBS (pH = 5), and then DOC-COOH PLGA NPs 
was added followed by addition of trastuzumab or ScFv IgG. The mixture was stirred 





4.3. Physical Characteristics 
4.3.1. Size Analysis, Surface Charge and Polydispersity Index 
 The Malvern Zetasizer Nano series (Montreal, Canada) was used to measure 
NP size, zeta potential (ZP), and the polydispersity index (PDI) for the NP 
formulations before and after freeze-drying as well as after trastuzumab and ScFv IgG 
attachment. Different NP formulations were suspended in deionized water and 
measurements were conducted at 25o ±1 C. Also, the yield of NPs recovery was 








4.3.2. Surface Morphology 
4.3.2.1. Transmission electron microscopy analysis  
NPs morphology for all formulations was assessed via Transmission electron 
microscopy analysis (TEM). TEM micrographs were obtained on a Hitachi HT7700 
from Hitachi, Ltd (Kyoto, Japan) which had high contrast and high resolution. The 
freeze-dried samples were suspended in water and then one drop of this suspension was 
placed into a small mold of the carbon-coated copper grid. The samples were stained 
with a negative stain of the specimen with 0.5% phosphotungstic acid. To evaporate 
the solvent, the samples were incubated for 5–10 min at room temperature (25 ± 2° C). 
 
 33 
4.3.2.2. Scanning electron microscopy analysis 
NPs morphology for all formulations was examined by Field Emission Electron 
Microscopy (SEM). It was seen under the SU8010 microscope from Hitachi High-
Technologies (Kyoto, Japan). The dried NPs were sprinkled onto a stub covered with 
an adhesive conductive carbon tab, then sputter coated with a 5-nm layer of chromium 
or 10 nm of gold by using Sputter Coater Q150T ES from Quorum. The NPs were 
imaged at 5 to 50 kV accelerating voltage. 
 
4.4. Identification of the Covalent Bond Between Linker and Ab 
A Bruker IFS 66v/S Fourier Transform Spectrometer (Bio-Rad-Win-IR, 
Saskatchewan Structural Sciences Centre) was used in the mid-IR range (infrared). All 
samples were mixed with spectroscopic-grade potassium bromide (KBr) and mold to 
prepare the pellets. The spectrum range was 4,000–400 cm-1 in the absorbance mode. 
This test identifies the covalent bond between Ab and the linker (BS3 and NHS/EDC) 
by a Fourier Transform Infrared (FTIR) spectroscopy. 
 
4.5. Docetaxel Loading Quantification 
The mass spectrometer was used to quantify the loading quantity of docetaxel 
in the NPs’ formulations. A fully validated quantitation procedure was performed on 
the equivalent docetaxel and internal standard (paclitaxel) MRM graphs using Analyst 
software version 1.6. The samples had to be extracted prior to reading them in mass. 




To prepare the standard, we used plain PLGA NPs and added different 
concentrations of docetaxel in methanol. 100 Bg/ml of docetaxel was prepared as stock 
solution. We then prepared serial dilutions (500, 1000, 2000, 4000, 8000, 16,000, 
32,000, and 64,000 Cg/ml) as standard samples with adding 10 Bl of an internal 
standard (paclitaxel). In Eppendorf tubes, we added 1 ml of each concentration and 
evaporated the methanol. We added 1 mg of plain PLGA NPs in each tube. The 
mixture was vortexed for one minute after we added 1 ml of acetone. The samples were 
sonicated in a water bath for 30 minutes and then centrifuged for 20 minutes at 8,000 
rpm. The supernatant was separated in a new tube to evaporate the acetone, and the 
pellet was resuspended in 1 ml of acetone by vortex-mixing, bath sonication, and 
centrifugation. Sequentially, we transferred the supernatant into the previous tube and 
evaporated the acetone. Finally, we added 500 Bl of methanol to dissolve the residue 
by vortex.  
For preparing of the PLGA-DOC NPs extraction, we followed the same steps, 
except we did not add docetaxel from stock. Also, preparing the quality control is 
needed in the dilutions of (2500, 30000, 50000 Cg/ml). The amount of docetaxel 
loaded in the NPs was quantified in a supernatant via a mass spectrometry method. 















4.6. Loading Quantification for Trastuzumab and Fragment ScFv IgG 
The amount of trastuzumab or ScFv IgG anti-HER2 attached to PLGA-DOC 
NPs was determined by using the bicinchoninic acid assay kit (Pierce™ Microplate 
BCA Protein Assay Kit, Thermo, Fisher) through indirect calculation by subtraction of 
the unbound Ab present in the collected supernatant during washing steps from the 
original amount. We performed the BCA protein assay by following the kit’s 
instructions. In this case, the supernatant of unmodified NPs (without the Ab 
attachment) was used as a standard blank. Also, the amount of Ab attached to NPs 
surface after FD was measured as a direct way by conducting the BCA assay on FD 
modified NPs formulations after Ab attachment. The absorbance of the samples was 
measured at 562 nm in the BioTek Microplate Reader using Gen5 data analysis 
















4.7. Evaluating in Vitro Release Pattern of Docetaxel from Modified NPs 
 In vitro drug release of DOC was performed on ester-PLGA-DOC-BS3-TrAb 
FD NPs for 120 hours in phosphate buffered saline (PBS) at different pH values (pH 
7.4 and 5.0). Thirty mg of NPs were suspended in PBS and then added into dialysis 
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cassette (Slide-A-Lyzer Dialysis Cassette; MWCO 3,500 Da from Thermo scientific). 
The dialysis cassette was submerged in PBS that was placed in the incubator shaker 
(5000I/R Shaker-platform promo) at 37°C with an agitation speed of 100 rpm. At the 
following time intervals (0, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours) 4 ml of the bulk 
media was taken out and replaced by equal volume of fresh media to prevent drug 
saturation. The samples were tested to identify the concentration of DOC released by 
mass spectrometer as described above. The following formulae calculated the 








4.8. Cell Culture 
SK-BR-3 and MCF-7 are human breast cancer cell lines. MCF-7 is considered a 
cell line with low expression of HER2, but SK-BR-3 overexpresses HER2. These cells 
were cultured in 75 cm2 flasks and incubated at a temperature of 37°C and a humidified 
atmosphere containing 5% CO2 (Carbon dioxide). MCF-7 cell lines were grown in 
Dulbecco’s Modified Eagle Medium (DMEM Sigma) while McCoy's 5A Medium was 
used for SK-BR-3 cell line. The media contained 10% fetal bovine serum (FBS) and 
1% penicillin (100 IU/ml)-streptomycin (100 µg/ml) solution, as dictated by the 
American Type Culture Collection (ATCC) guidelines. Also, a 0.25% trypsin-EDTA 




4.9. Cytotoxicity Assay in Vitro  
 MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt) cell viability assay was performed on SK-BR-
3 cell line that was plated into 96 well plates at a cell density of 15,000 per well and 
left for 24 hours to allow the attachment of the cells. Subsequently, the growth medium 
was removed and different formulations were added at various concentrations (0, 1, 
2.5, 5, 10, 100, 1000, 10,000 ng/ml) and incubated for 48 hours. After that, the MTS 
was added to each well of the plate. The absorbance was measured at 490 nm using a 
microplate reader (BioTek Microplate Reader) using Gen5 data analysis software. The 
IC50 values were calculated by the formula of logarithmic curves, and cell viability 
percentage was calculated using the following equation: 
 







4.10. Measuring HER2 Expression 
4.10.1. Flow Cytometry Analysis  
1.5 x 105 cells of each cell line (MCF-7 and SK-BR-3) were plated in each well 
of 6-well plates with the medium and incubated for 24 hours. After that, cells were 
treated with the same concentration of DOC (as a standard) attached to Ab PLGA-
DOC NPs. The plate was incubated for 48 hours. Then a 0.25% trypsin-EDTA solution 
was used to harvest adherent cells from the plate. After centrifugation, the cells were 
washed twice with ice cold PBS. FITC conjugated with Anti-HER-2/neu (Neu 24.7) 
FITC (from Biosciences) was used to stain the HER2 receptor on the cells. After 
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incubation, unbound Ab was washed with ice cold FACS buffer twice prior to flow 
cytometry analysis. 
 
4.10.2.  Western Blot Analysis  
Protein was isolated from SK-BR-3 cell line after NP treatment by lysis with 
sample buffer and then to ensure an equal amount was loaded on the gel, proteins 
concentration was assayed using the BCA protein assay kit. For different types of NPs 
formulations, HER2 expression was measured by 8% polyacrylamide gel which were 
loaded with 15 Bl of sample. After electrophoresis gels were transferred to a 
nitrocellulose membrane and non-specific binding was primarily blocked with 5% 
skim milk solution that has Purified Mouse Anti-Human ErbB2 Ab from BD 
Biosciences, at + 4°C overnight on a rocking platform. After incubating the primary 
Ab, the membrane washed two times with PBS containing 0.05 % Tween20. Goat 
Anti-Mouse IgG was used to react with the proteins at room temperature for an hour. 
After the washing step, the protein bands were visualized using ChemiDoc XRS; Bio-
Rad Laboratories, Hercules, CA). Immunoblotting with GAPDH was used as a protein-
loading control. The quantifications were performed by a digital image J system and 
Quantity One software. 
 
4.11. Statistical Analysis 
 Data were analyzed by descriptive statistics calculating the mean and standard 
deviation (mean	±	SD) for continuous variables. Analysis of variance (ANOVA) with 
multiple comparison (Tukey’s and Pairwise Comparison) tests were performed to 
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5. RESULTS  
ü First objective: To develop PLGA polymeric NPs loaded with docetaxel and 
decorated with a humanized monoclonal antibody (trastuzumab) or fragment ScFv 
IgG anti-HER2 on the NPs’ surface by using two different cross-linking agents BS3 




5.1. NP Yield Percentage  
5.1.1. Solvent Evaporation Preparation Technique 
To prepare NPs, the first o/w emulsion must be prepared first, and the organic 
solvent must be evaporated. When ethyl acetate was used as the organic solvent in the 
case of ester-terminated PLGA, it provided a reasonable NPs yield, as shown in Tables 
6 and 7. However, the yield was lower when ethyl acetate was used with COOH 
terminated PLGA.  
 
5.1.1.1. Plain PLGA NPs yield percentage 
Table 6 summarizes the results for the yield of plain PLGA NPs formulations 
using both ester- and COOH-terminated PLGA with different organic solvent. Ethyl 
acetate was used first based on its safety as determined by the FDA. However, COOH 
PLGA polymer was used to prepare NPs with ethyl acetate which showed a low yield 
percentage (around 20 to 25%). Whilst, chloroform provided a better yield percentage 




Table 6. Percentage of yield for plain NPs formulations using ester- and acidic-
terminal of PLGA (n=5). 
NPs Formulation Yield (%) Average ± SD 
Plain PLGA ester in ethyl acetate 20.34 ± 4.59	 
Plain PLGA ester -1 mg/ml sucrose in ethyl acetate 22.62 ± 1.65  
Plain PLGA ester-1.7 mg/ml sucrose in ethyl acetate 25.245 ± 1.45  
Plain PLGA COOH-1 mg/ml sucrose in ethyl acetate 15.22 ± 2.36  
Plain PLGA COOH- 1 mg/ml sucrose in chloroform 26.59 ± 12.14  
Plain PLGA COOH-1.7 mg/ml sucrose in chloroform 33.2  ± 3.99  
 
 
5.1.1.2. Yield percentage of ester PLGA NPs loaded with docetaxel  
 Table 7 shows the yield percentages for DOC-NPs formulations using the 
ester-terminal of PLGA as well as different amounts of cryoprotectant (sucrose) in 
nanosuspension formulation. To improve the yield of dispersed NPs, the cryoprotectant 
sucrose, which acts to decrease aggregation and stress during the NPs formulation, was 
added in increasing concentrations. NPs yield did not change with increasing sucrose 
concentration (table 7). Adding 1 mg/ml of sucrose to PLGA ester-DOC-BS3 gave 
55.63 ± 2.02 yield percentage. Simultaneously, increasing the quantity of sucrose (up 








Table 7. Data of yield percentage for ester-terminal PLGA encapsulating DOC (n=5). 
NPs Formulation Yield (%) Average ± SD 
PLGA ester-DOC 46.88 ±	4.37  
PLGA ester-DOC-BS3 54.19 ±	4.96  
PLGA ester-DOC-BS3-1 mg/ml sucrose 55.63 ±	2.02  
PLGA ester-DOC-BS3-1.7 mg/ml sucrose 54.93 ± 4.27  
PLGA ester-DOC-BS3-3.3 mg/ml sucrose 51.42 ± 13.18  
PLGA ester-DOC-BS3-5 mg/ml sucrose 46.27 ±	13.03  
PLGA ester-DOC-BS3-6.7 mg/ml sucrose 52.93 ±	15.93  





5.1.1.3. Yield percentage of COOH PLGA NPs loaded with docetaxel 
 The yield percentage that resulted from using different solvents (ethyl acetate 
and chloroform), as well as different quantities of cryoprotectant is shown in Table 8. 
The yield percentage for COOH PLGA NPs is larger than that of ester PLGA (around 
65%, and 45% respectively), which means COOH PLGA has higher recovery rate. 
With respect to ester PLGA NPs, the quantity of cryoprotectant did not cause any 
significant change in the yield percentages of the formulations. For example, having 1 
mg/ml of sucrose in PLGA COOH-DOC NPs showed about 60% yield; whereas, the 
same yield percentage showed when the sucrose concentration increased to 3 mg/ml 
and higher. Furthermore, loaded COOH PLGA NPs confirmed that chloroform 





Table 8. Results of yield percentage using COOH PLGA terminal (n=5). 
NPs Formulation Yield (%) Average ± SD 
PLGA COOH-DOC-1 mg/ml sucrose in ethyl acetate 16.12 ± 2.49  
PLGA COOH-DOC-1 mg/ml sucrose in chloroform 60.37 ± 1.36  
PLGA COOH-DOC-1.7 mg/ml sucrose in chloroform 69.52 ± 2.61  
PLGA COOH-DOC-3 mg/ml sucrose in chloroform 63.97 ± 7.12  
PLGA COOH-DOC-5 mg/ml sucrose in chloroform 58.56 ± 11.43  
PLGA COOH-DOC-6.7 mg/ml sucrose in chloroform 55.06 ± 12.45  
PLGA COOH-DOC-8.3 mg/ml sucrose in chloroform 62.91 ± 4.68  
PLGA COOH-DOC-10 mg/ml sucrose in chloroform 62.2 ± 7.04  
 
 
5.1.2. Precipitation Preparation Technique 
 The NanoAssemblr machine prepared NPs formulations by molecular self-
assembly mixing in a millisecond time period. There are many criteria for controlling 
particle size, such as flow rate, polymer composition, and the ratio between oil and 
water phases. Different concentrations were used to reach small particles; however, 
some of the formulations were lost during Freeze-dry (FD), and it did not turn from the 
solid phase to powder (instead of becoming liquid, NA).  
 
5.1.2.1. Yield percentage of ester-loaded PLGA NPs  
 Different amount (5%, 6.5%, and 10% w/v) of ester PLGA were dissolved in 
acetone as well as a different quantity of docetaxel (3%, 5%, and 10% w/v). Several 
ratio percentage were used to find the optimal concentration for forming NPs. Adding 
5% PLGA ester with to 3% DOC gave 42% yield percent; when the DOC quantity 
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increased to 10% the result was with a higher yield percentage (63%). However, when 
the quantity of PLGA ester increased, no significant increase in the yield percentage 
was noted. With 5% of PLGA ester and 3% of DOC the yield percentage was 42% 
contrary to the yield percentage which was 35% for 10% PLGA ester and 3% DOC 
NPs. The use of COOH PLGA gave a high yield percentage compared with that of 
ester PLGA. Similar to ester-PLGA NPs increasing the quantity of DOC (3%, 5%, and 
10%) did not show any significant increase in the yield percentage of COOH-PLGA-
DOC (60.06%, 47.8%, and 57.77%, respectively) (Table 9). 
 
 
Table 9. Yield percentage for PLGA ester and COOH formulations encapsulating 
docetaxel (n=1). 
NPs Formulation Yield (%) NPs Formulation Yield (%) 
PLGA ester 5% mg/ml-
DOC 3% 42.3 
PLGA COOH 5% mg/ml-
DOC 3% 60.06 
PLGA ester 5% mg/ml-
DOC 5% NA 
PLGA COOH 5% mg/ml-
DOC 5% 47.8 
PLGA ester 5% mg/ml-
DOC 10% 63.4 
PLGA COOH 5% mg/ml-
DOC 10% 57.77 
PLGA ester 6.5% mg/ml-
DOC 3% NA 
PLGA COOH 6.5% mg/ml-
DOC 3% 33.24 
PLGA ester 6.5% mg/ml-
DOC 5% NA 
PLGA COOH 6.5% mg/ml-
DOC 5% 92.24 
PLGA ester 6.5% mg/ml-
DOC 10% 31.05 
PLGA COOH 6.5%mg/ml-
DOC 10% 88 
PLGA ester 10%mg/ml-
DOC 3% 35.36 
PLGA COOH 10% mg/ml-
DOC 3% NA 
PLGA ester 10% mg/ml-
DOC 5% 37.27 
PLGA COOH 10% mg/ml-
DOC 5% 48.6 
PLGA ester 10% mg/ml-
DOC 10% NA 
PLGA COOH 10% mg/ml-




5.2.  Identification of Covalent Bond by FTIR 
The peak around 1750 cm-1 wavelength is one of the characteristics of carbonyl 
bond C=O presence of PLGA. The presence of the covalent conjugation between both 
ester- and acidic-terminal PLGA NPs and target ligand (whole IgG and ScFv anti-
HER2) can be confirmed by detecting the amide bond. Usually, amide bond appears 
around 1640 cm-1 wavelength. The differences in the wavelength intensity for 
unmodified and modified ester NPs, accordingly the presence of the amide bond was 
confirmed around 1650 cm-1 (Figure 7). Figure 8 represents the same concept of 
COOH-terminated NPs.  
 
 
Figure 7. The FTIR derivative spectra of ester-terminated PLGA NPs: PLGA ester-
DOC (yellow), PLGA ester-DOC-TrAb (blue), and PLGA ester-DOC-ScFv (red). Data 
is represented in absorbance units versus wavelength (cm-1). 
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Figure 8. The FTIR derivative spectra of acidic terminated PLGA NPs. PLGA COOH-
DOC (red), PLGA COOH-DOC-TrAb (yellow), and PLGA COOH-DOC-ScFv (blue). 





















ü Second Objective: To study physicochemical characterization of modified 
nanoparticles in terms of: 
a) Size, zeta potential, polydispersity index and surface imaging  
b) Quantification of docetaxel loading and encapsulation efficiency  
c) Quantification of Ab attachment in PLGA NPs that encapsulated docetaxel 




5.3. Physical Characterization 
5.3.1. Size Analysis, Surface Charge and Polydispersity Index  
Size, PDI and ZP are critical parameters to consider prior to starting in vitro and 
in vivo experiments because it affects NPs uptake fundamentally. These measurements 
were taken before and after FD as well as after Ab attachment.  
 
5.3.1.1. Solvent evaporation technique 
5.3.1.1.1. Size, ZP, and PDI for ester-terminal PLGA NPs 
Different quantity of sucrose was used to determine its effect on NPs size, ZP 
and PDI before and after FD (Table 10). The average size of plain NPs without BS3 is 
150.9 ± 1.786 nm before FD, which is larger than plain NPs containing BS3 (141.34 ± 
1.2 nm prior FD). Importantly, the data showed that increasing the quantity of 
cryoprotectant (1.7mg/ml) led to smaller NPs size after FD (257.2 ± 15.77 nm) and 
reduced the negative charge on NPs surface to - 4.7 ± 0.447 ZP. Using only 1 mg/ml 
of sucrose gave particle sizes above 500 nm in diameter, which would affect the uptake 
of the NPs. 
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5.3.1.1.2. Size, ZP, and PDI for COOH-terminal PLGA NPs 
Similar to ester-PLGA NPs different quantity of sucrose as well as organic 
solvent (ethyl acetate and chloroform) were used to identify its effect on COOH-PLGA 
NPs loaded with DOC (Table 12). The average size of DOC NPs is 329.8 ± 9.39 nm 
after FD, which showed that increasing the amount of cryoprotectant helps to reduce 
the aggregation during FD process. Another observation is that the use of ethyl acetate 
created smaller sizes but produced lower yield percentage in the case of acidic PLGA 
NPs. For instance, the size for PLGA COOH-DOC-1 mg/ml sucrose was around 133.8 
± 1.52 nm before FD when the ethyl acetate was used as organic solvent; where, the 
using of chloroform gave larger size (228.2 ± 3.61 before FD). In addition, using 1.7 
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mg/ml of sucrose gave a size of 329.8 ± 9.39 nm for COOH PLGA encapsulated DOC, 
in contrast with COOH PLGA-DOC with 1 mg/ml of sucrose (854.6 ± 22.93 after 
FD). 
 
Table 11. Acid-terminal PLGA using different quantities of cryoprotectant (n=5). 
NPs Formulation 


























































































5.3.1.1.3. Size, ZP, and PDI for ester and COOH PLGA NPs-encapsulated DOC and 
modified with anti-HER2 
Both TrAb and fragment Ab were attached to the surface of different NPs 
formulations. Therefore, it is necessary to measure the size, ZP, and PDI after the 
attachment. The size of both ester and acidic NPs-encapsulated DOC did not show 
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significant differences between the whole Ab and ScFv anti-HER2 when attached to 
the surface (Table 12). For all formulations, the average size was less than 400 nm. Ab 
attachment increased the surface charge to reach neutral.  
 
 
Table 12. Physiochemical characteristics of trastuzumab and ScFv IgG anti-HER2 
considering both linkers (BS3 and NHS/EDC; n=5). 
NPs Formulation Mean Size ± SD After FD 
Mean PDI ± 
SD After FD 
Mean ZP ± 
SD After FD 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose-300 Bg TrAb 379.3 ± 3.04 0.34 ± 0.01 -0.14 ± 0.27 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose-300 Bg ScFv 312 ± 8.77 0.35 ± 0.03 0.02 ± 0.07 
PLGA COOH-DOC-NHS/EDC-
1.7mg/ml sucrose-300 Bg TrAb 382.5 ± 21.5 0.38 ± 0.02 0.05 ± 0.04 
PLGA COOH-DOC-NHS/EDC-
1.7mg/ml sucrose-300 Bg ScFv 367.2 ± 8.46 0.33 ± 0.04 0.28 ± 0.10 
 
 
5.3.1.2.  Precipitation technique 
5.3.1.2.1. Ester-terminal PLGA NPs 
The precipitation technique yielded very large NPs with an average size greater 
than 2,000 nm. This large size affects the physiochemical properties of NPs 
formulations, which would prevent cell uptake and immediately be cleared from the 
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body. All the formulations had high polydispersity index, which indicates there was no 
uniformity in the size of NPs (Table 13). 
 
 
Table 13. Size, PDI, and ZP ester-terminal PLGA encapsulating docetaxel before FD 
(n=1).  
NPs Formulation Mean Size ± SD Before FD 
Mean PDI ± 
SD Before FD 
Mean ZP ± 
SD Before FD 
PLGA ester 50 mg/ml-DOC 3 mg/ml 2980 ± 207.3 1 7.55 ± 0.36 
PLGA ester 50 mg/ml-DOC 5 mg/ml 2078 ± 201 0.97 ± 0.05 4.17 ± 0.34 
PLGA ester 50 mg/ml-DOC 10 mg/ml 2268 ± 148.5 0.97 ± 0.02 1.11 ± 0.27 
PLGA ester 65 mg/ml-DOC 3 mg/ml 1066 ± 68.6 0.64 ± 0.09 -0.01 ± 0.07 
PLGA ester 65 mg/ml-DOC 5 mg/ml 2030 ± 75.8 0.99 ± 0.02 -4.44 ± 0.34 
PLGA ester 65 mg/ml-DOC 10 mg/ml 2931 ± 31.8 1 -7.68 ± 0.55 
PLGA ester 100 mg/ml-DOC 3 mg/ml 2038 ± 107.5 0.99 ± 0.2 -4.29 ± 0.23 
PLGA ester 100 mg/ml-DOC 5 mg/ml 2656 ± 206.4 1 -8.05 ± 0.60 




5.3.1.2.2. COOH terminal PLGA NPs 
Increasing the quantity of COOH PLGA polymer reduced the mean of NPs size 
to be about 1,500 nm and decreased PDI to approximately 0.768 ± 0.05. Regardless of 
this slight improvement, all formulations were very large in size and un-uniform, 
which affects the physical properties of formulations. (Table 14)  
 
Table 14. Physical characteristics of COOH PLGA-carried docetaxel prior FD (n=1). 
NPs Formulation Mean Size ± SD Before FD 
Mean PDI ± 
SD Before FD 
Mean ZP ± 
SD Before FD 
PLGA COOH 50 mg/ml-DOC 3 mg/ml 3664 ± 635.6 1 -3.21 ± 0.46 
PLGA COOH 50 mg/ml-DOC 5 mg/ml 2443 ± 299.5 1 -4.76 ± 0.45 
PLGA COOH 50 mg/ml-DOC 10 
mg/ml 4405 ± 430.7 0.767 ± 0.24 -0.29 ± 0.15 
PLGA COOH 65 mg/ml-DOC 3 mg/ml 1944 ± 230.4 0.998 ± 0.09 -5 ± 0.43 
PLGA COOH 65 mg/ml-DOC 5 mg/ml 1587 ± 422.2 0.939 ± 0.09 0.02 ± 0.07 
PLGA COOH 65 mg/ml-DOC 10 
mg/ml 1430 ± 176.5 0.837 ± 0.08 -5.1 ± 0.28 
PLGA COOH 100 mg/ml-DOC 3 
mg/ml 1413 ± 167.4 0.756 ± 0.08 -0.671 ± 0.15 
PLGA COOH 100 mg/ml-DOC 5 
mg/ml 1704 ± 156.3 0.768 ± 0.05 0.4 ± 0.07 
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 As a result of the above data, we found that the ideal way to prepare polymeric 
NPs was solvent evaporation technique, which gave the highest yield as well as the 
best physical characteristics in terms of size, surface charge (ZP), and polydispersity 
index (PDI). Following are the final formulations used for further analysis based on the 
positive possibility of targeting HER2 breast cancer raptors: PLGA ester-DOC-BS3-
1.7mg/ml sucrose-300 Bg TrAb, PLGA ester-DOC-BS3-1.7mg/ml sucrose-300 Bg 
ScFv, PLGA COOH-DOC-NHS/EDC-1.7mg/ml sucrose-300 Bg TrAb, and PLGA 
COOH-DOC-NHS/EDC-1.7 mg/ml sucrose-300 Bg ScFv. 
 
 
5.3.2.  Surface morphology  
5.3.2.1. TEM 
The NPs formulations were visualized by TEM to analyze their morphological 
characteristics, such as size, shape, and PDI. NPs had quasi-spherical geometry with 
uniformity in the dispersion (Figure 9). The images also confirmed that the conjugation 
of anti-HER2 may occur without affecting the morphology of the NPs. The diameter of 
NPs was larger in the measurement by Zetasizer (a Malvern instrument) compared to 
the TEM measurement because TEM provides the results of a dry state of NPs 
formulations, whereas Zetasizer collects results from the NPs in hydrated form. Also, 
TEM can show the image of a single particle, whereas Zetasizer provides an estimate 
of size average, which favors the larger NPs distributions. In addition, Zetasizer 
measures size by determining the dynamic light scattering (DLS), which is a different 
form of analysis.  
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Figure 9. Surface morphology of both ester and acidic PLGA-encapsulated docetaxel 
and conjugated by either trastuzumab (TrAb) as a whole IgG antibody or single-chain 












Scanning electron microscopy confirmed the size, shape, and PDI. Figures 10 
and 11 demonstrate the images of different formulations obtained by using chromium 
and gold to coat NPs; this coating is necessary because direct beams melt the PLGA 
polymers. The NPs were chosen randomly. The pictures emphasized the uniformity of 
NPs, with near spherical in shape. SEM results, like the TEM results discussed above, 





























Figure 10. Surface morphology of both ester and acid PLGA-encapsulated docetaxel 
conjugate by either trastuzumab (TrAb) as a whole IgG antibody or single-chain 























Figure 11. Surface morphology of both ester and acid PLGA-encapsulated docetaxel 
conjugate by either trastuzumab (TrAb) as a whole IgG antibody or single-chain 























5.4.  Docetaxel-Loading in NPs Formulations 
The initial concentration of docetaxel used in all formulations is 3 mg/ml; this 
amount was chosen based on the previous project in our lab that indicated 3 mg is the 
most efficient quantity (Sadat, 2015). There was no statistical significance in DOC 
loading between ester or acidic PLGA for unmodified NPs formulations. There was a 
substantial difference in DOC loading for both ester and acid NPs when ScFv anti-
HER2 was attached to the NPs surface. The tests for encapsulation efficiency showed 
that there were significant differences in the case of ester NPs and between modified 
NPs with TrAb and unmodified NPs (PLGA ester-DOC- versus PLGA ester-DOC-
TrAb). Additionally, poor encapsulation of DOC appeared in modified acidic PLGA 
formulations when ScFv was attached; therefore, there was a statistical difference 














Table 15. Docetaxel loaded in PLGA through mass spectrometry analysis and the 
percent of encapsulation efficiency (n=6). 
NPs Formulation Average loading ± SD 
tu/wu Of NPs EE % ± SD 
PLGA ester-DOC-BS3-1.7mg/ml sucrose 
 21.78 ± 3.33  
49.8 % ± 
6.1 
PLGA ester-DOC-BS3-1.7mg/ml sucrose-300 Bg 
TrAb 
 
18.92 ± 3.86  70.8 % ± 12.4 
 PLGA ester-DOC-BS3-1.7mg/ml sucrose- 300 Bg 
ScFv 
 
14.88 ± 3.62  57.6 % ± 11.6 
 PLGA COOH-DOC-1.7mg/ml sucrose in chloroform 
 25.23 ± 2.32  
68.5 % ± 
5.4 
PLGA COOH-DOC-NHS/EDC-1.7mg/ml sucrose in 
chloroform-300 Bg TrAb 
 
20.70 ± 6.61  85.6 % ± 19.6 
PLGA COOH-DOC-NHS/EDC-1.7mg/ml sucrose in 
chloroform- 300 Bg ScFv 
 











Figure 12. The differences between DOC loading in ester- and COOH- terminal 
PLGA. The same quantity of cryoprotectant (1.7 mg/ml) was used in all formulations. 
The statistical significance between and within the groups were represented by 
encompassing lines marked with sign (*). Horizontal column represent PLGA NPs 
before anti-HER2 attachment, diagonal column represent PLGA NPs attached to TrAb, 
and vertical column represent PLGA NPs attached to ScFv. The level of significance 
was set to p < 0.05 (ANOVA followed by Tukey’s multiple comparison test method). 






Figure 13. The differences between DOC encapsulation efficiency for both ester- and 
COOH- terminal PLGA formulations. The same quantity of cryoprotectant (1.7 mg/ml) 
was used in all formulations. The statistical significance between groups are 
represented by encompassing lines marked with the sign (*). Horizontal column 
represent PLGA NPs before anti-HER2 attachment, diagonal column representative 
PLGA NPs attached to TrAb, and vertical column represent PLGA NPs attached to 
ScFv. The level of significance was set to p < 0.05 (ANOVA followed by Tukey’s 



















5.5. Anti-HER2 Attachment Quantification 
5.5.1. Indirect Measurement of Ab Conjugation 
The amount of anti-HER2 attached to PLGA-DOC NPs was determined by 
indirect calculation, in which the unbound Ab present in the collected supernatant 
during washing steps was subtracted from the original amount.  
 
5.5.1.1. BS3 linker 
 After testing, we found that 1.5 mg BS3 is the most efficient amount to use for 
Ab attachment, and increasing the quantity of BS3 produces no significant increase in 
the Ab attachment (Sadat, 2015). Using 300 µg of anti-HER2 Ab resulted in a 
considerable quantity of Ab conjugation, reaching about 22.8 µg per mg of PLGA 
ester-DOC-BS3 NPs.  
 
Table 16. Amount of whole Ab (trastuzumab) attached to ester PLGA-DOC NPs and 
the percentage of the attachment efficiency by indirect quantification (n=6). 
NPs Formulation 
Trastuzumab 
attachment (xg)/NPs mg 
± SD 
Trastuzumab 
attachment efficiency % 
± SD 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose-300Bg TrAb 22.8 ± 3.78 45.8	±	6.9 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose-150Bg TrAb 10.11 ± 2.5 40	±	9.5 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose-75Bg TrAb 0.86 ± 5.31 6.9	±	18.4 
PLGA ester-DOC-BS3-1.7mg/ml 





Table 17. Amount of ScFv anti-HER2 attached to ester PLGA-DOC NPs and the 




mg ± SD 
Trastuzumab 
Attachment efficiency 
% ± SD 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose-300µg-ScFv  ~100 % ~100 % 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose-150µg ScFv  ~100 % ~100 % 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose 75µg ScFv  ~100 % ~100 % 
PLGA ester-DOC-BS3-1.7mg/ml 
sucrose 37.5µg ScFv ~100 % ~100 % 
 
5.5.1.2. NHS/EDC linker: 
As the above result for BS3 suberate showed, NHS/EDC provided better Ab 
attachment when 300 µg was used for PLGA COOH-DOC. Around 23.3 µg of whole 
Anti-HER2 Ab was attached to 1 mg of NPs (Table 18); while, 100% of the ScFv, got 
attached to PLGA COOH-DOC (Table 19). 
 
 
Table 18. Amount of whole Ab (trastuzumab) attached DOC-COOH PLGA NPs and 
the percentage of the attachment efficiency by indirect quantification (n=6). 
NPs Formulation 
Trastuzumab 
attachment (xg)/NPs mg 
± SD 
Trastuzumab 
attachment efficiency % 
± SD 
PLGA COOH-DOC-NHS/EDC-
1.7mg/ml sucrose-300Bg TrAb 23.31 ± 2.62 56.7 ± 6.3 
PLGA COOH-DOC-NHS/EDC-
1.7mg/ml sucrose-150Bg TrAb 15.21 ± 1.31 73.9 ± 6.3 
PLGA COOH-DOC-NHS/EDC-
1.7mg/ml sucrose-75Bg TrAb ~100 % ~100 % 
PLGA COOH-DOC-NHS/EDC-
1.7mg/ml sucrose-37.5Bg TrAb ~100 % ~100 % 
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Table 19. Amount of ScFv anti-HER2 attached to DOC-COOH PLGA and the 
percentage of the attachment efficiency by indirect quantification (n=6). 
NPs Formulation 
Trastuzumab 
attachment (xg)/NPs mg 
± SD 
Trastuzumab 
attachment efficiency % 
± SD 
PLGA COOH-DOC-NHS/EDC-
1.7mg/ml sucrose-300µg) ScFv  ~100 % ~100 % 
PLGA COOH-DOC- NHS/EDC-
1.7mg/ml sucrose-150µg ScFv  ~100 % ~100 % 
PLGA COOH-DOC- NHS/EDC-
1.7mg/ml sucrose-75µg ScFv  ~100 % ~100 % 
PLGA COOH-DOC-NHS/EDC-
1.7mg/ml sucrose-37.5µg ScFv  ~100 % ~100 % 
 
 
5.5.2. Direct Measurement of Ab Conjugation 
In this case, the amount of Ab attached to the NPs surfaces after FD was 
measured as a direct way by conducting the BCA assay (Table 20). TrAb attachment 
was up to 16.33 ± 2.69 Bg/mg of acidic PLGA-DOC-NHS/EDC NPs which was higher 
than ester-PLGA-DOC-BS3 (14.1 ± 2.51 Bg/mg of NPs). However, the PLGA ester-
















Table 20. Direct quantification of anti-HER2 attached to DOC PLGA NPs (n=6). 
NPs Formulation Trastuzumab attachment (xg)/NPs mg ± SD 
PLGA ester-DOC-BS3-1.7mg/ml sucrose-300Bg 
TrAb 14.1 ± 2.51 
PLGA ester-DOC-BS3-1.7mg/ml sucrose-300µg-

























5.6.  Evaluation of In Vitro Release of Docetaxel from Modified NPs  
The in vitro drug release profile for modified ester-PLGA NPs was analyzed at 
neutral (pH 7.4) and acidic (pH 5.0) PBS for 120 hours. The results are presented in 
Figure 14. A calibration curve was developed in a range from 125-64,000 ng/ml (R2 
=0.998), and the accuracy and precision of data were determined by the validated MS 
method to identify the DOC concentration and evaluate the drug release. An early burst 
release was detected in the first 24 hours. After that, a control release occurred as a 
result of diffusion of DOC through the PLGA polymeric matrix. 
5.6.1. Ester PLGA formulation 
The release of the drug (DOC) from ester PLGA conjugated with whole IgG 
(TrAb) was found to be faster in acidic conditions; more than 50% of DOC was 
released within the first day at pH 5.0, whereas it took 72 hours to attain a comparable 
level of DOC release at pH 7.4. 
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 Figure 14. The in vitro release profiles of docetaxel from ester-PLGA NPs conjugated 
with whole anti-HER2 (TrAb) at pH 5.0 and 7.4 in PBS buffer under 100 rpm and 
37oC. The level of significance was set to p < 0.05 (ANOVA). Each line represents the 














ü Third Objective: To evaluate cell viability and IC50 in SK-BR-3 cell line 
 
 
5.7.  Cell Cytotoxicity 
In vitro cytotoxicity assay was conducted with all NPs formulations (modified 
and unmodified NPs). Then, the results were compared to the conventional DOC and 
Herceptin which are available in the market. The percentage of cell viability as well as 
the 50% inhibitory concentration (IC50) were calculated to evaluate the difference in 
the efficacy of docetaxel in modified NPs formulations (conjugated with targeting 
moiety) in treating SK-BR-3 (HER2-positive) cell line. All experiments were 
conducted four times. 
 
5.7.1.  Cell Viability Percentage 
The following formulations were tested on SK-BR-3 cells to determine the cell 
viability using the MTS assay (conventional DOC, conventional Herceptin, 
conventional combination DOC and Herceptin, plain PLGA ester NPs, plain PLGA 
COOH NPs, PLGA ester-DOC NPs, PLGA COOH-DOC NPs, PLGA ester-DOC-
TrAb, PLGA ester-DOC-ScFv, PLGA COOH-DOC-TrAb, and PLGA COOH-DOC-
ScFv). Statistical analysis showed that plain NPs for both ester- and acidic-terminated 




Figure 15. In vitro cytotoxicity of plain PLGA ester NPs, and plain acidic PLGA NPs in SK-BR-
3 cells at 48 hours. Cell viability was evaluated by MTS assay. Data are represented as mean 
percentage ± SD (n=4). 
 
 
Almost all DOC-loaded NPs formulations showed a significant advanced 
toxicity to cancer cell compared to conventional DOC and the combination of DOC 
and Herceptin. Modified NPs showed more significant cytotoxicity than unmodified 
NPs (PLGA encapsulated DOC without Ab conjugation). In general, the viability of 
SK-BR-3 breast cells decreased with increases in drug concentration. The results of 
cells viability percentage for ester PLGA loaded with DOC and the modified form of 
ester NPs with both TrAb and ScFv were compared to conventional DOC and the 
combination of conventional DOC and Herceptin in Figure 16. The percentage of cell 
viability was around 62% for the cells treated with ester-PLGA-DOC-TrAb and 78% 
for ester-PLGA-DOC-ScFv (0.1 Cg/ml of DOC). The percentage of cell viability for 
acidic PLGA DOC NPs was provided in Figure 17 to define the differences when both 
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modified and unmodified formulations of acidic NPs were compared to what is being 
used now in the market (DOC and Herceptin).  
 
 
Figure 16. The percentage of in vitro cell viability for conventional docetaxel, 
combination of conventional docetaxel and Herceptin, PLGA ester-DOC, PLGA ester-
DOC-TrAb, PLGA ester-DOC-ScFv in SK-BR-3 cells at 48 hours. Cell viability was 
evaluated by MTS assay. The statistical significance between NPs formulations and the 
conventional DOC were represented by the sign of (*); the significance of NPs 
formulations in comparison with the combination of conventional DOC and Herceptin 
are represented by the sign (+). The level of significance was set to p < 0.05. Data are 




 Figure 17. The percentage of in vitro cell viability for conventional docetaxel, 
combination of conventional docetaxel and Herceptin, PLGA acidic-DOC, PLGA 
acidic-DOC-TrAb, and PLGA acidic-DOC-ScFv. The statistical significance between 
NPs formulations and the conventional DOC were represented by the sign (*); the 
significance of NP formulations in comparison with the combination of conventional 
DOC and Herceptin are represented by the sign (+). The level of significance was set to 








 We compared all modified NPs to conventional medications as presented in 
Figure 18 to determine whether it confirmed the effectiveness of modified NPs 
formulations in delivering DOC to the HER2 breast cancer cell line and in improving 
the toxicity to the cancers cells. Both ester modified NPs (with TrAb or ScFv) showed 
more potent cytotoxic, followed by acidic modified NPs. Moreover, Figure 19 
highlights the significance of whole IgG anti-HER2 in ester- and acidic-terminated 
PLGA NPs as well as ScFv anti-HER2 in both ester- and acidic-terminated PLGA NPs. 
PLGA ester-DOC-TrAb showed more cytotoxicity than PLGA COOH-DOC-TrAb. 
The percentage of cell viability was around 35% for ester modified formulations in 
DOC concentration of 10 Cg/ml; whereas, acidic modified NPs had cell viability 
percentage above 50%. The destructive effects of ester PLGA modified with ScFv also 





Figure 18. The percentage of in vitro cell viability for all modified PLGA NPs 
formulations, conventional docetaxel, combination of conventional docetaxel and 
Herceptin, PLGA ester-DOC-TrAb, PLGA ester-DOC-ScFv, PLGA acid-DOC-TrAb, 
and PLGA acid-DOC-ScFv in SK-BR-3 cells at 48 hours. Cell viability was evaluated 
by MTS assay. The level of significance was set to p < 0.05. Data are represented as 




Figure 19. The percentage of in vitro cell viability for all modified PLGA NPs 
formulations, in comparison to each other; ester-DOC-TrAb, PLGA ester-DOC-ScFv, 
PLGA acidic-DOC-TrAb, and PLGA acidic-DOC-ScFv. The statistical significance 
between NPs formulations are represented by the sign of (*). The level of significance 
was set to p < 0.05. Data are represented as mean percentage ± SD (n=4). 
 
 
Lastly, the modified PLGA showed a powerful cytotoxic ability compared with 
conventional DOC and Herceptin in the market. As a result, examining ester-PLGA 
formulations (PLGA ester-DOC, PLGA ester-DOC-TrAb, and PLGA ester-DOC-
ScFv) alongside conventional DOC alone or the combination of conventional DOC and 
Herceptin revealed the significant targeted delivery system with whole Ab or with the 
ScFv (Figure 16). In addition, Figure 17 compares the percentage of cell viability for 
PLGA acid-DOC, PLGA acid-DOC-TrAb, PLGA acid-DOC-ScFv and conventional 
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medications; the above bar chart demonstrates the significance of modified 
formulations in lowering cell viability.   
 
5.7.2. The Half Maximal Inhibitory Concentration (IC50) 
The cytotoxicity quantitatively resulting in 50% growth inhibition (IC50) was 
calculated by the formula of logarithmic concentration effect curves, in which the 
optical density of the control well was taken as 100%. Table 21 gives IC50 for SK-BR-
3 cell line after 48 hours incubated with different formulations. Modified PLGA ester-
DOC conjugated with ScFv exhibited the highest cytotoxicity (the lowest viability) 
followed by modified PLGA ester-DOC-TrAb in comparison with all cases of 
conventional DOC. Interestingly, modified acid PLGA showed less viability compared 
to modified ester PLGA, whereas the IC50 for PLGA acidic-DOC-ScFv was 2.11 ng/ml 
and 3.72 for the PLGA Acid-DOC-TrAb. The differences in IC50 for all formulations 












Table 21. Mean IC50 ± SD (cytotoxicity) of different docetaxel formulations on SK-
BR-3 human breast cancer cells by MTS assay after 48 hours. Data are represented as 
mean. 
NPs Formulations IC50 (ng/ml) ± SD 
Conventional DOC 8.23 ± 0.21 
PLGA ester DOC NPs 8.34 ± 0.25 
PLGA acid DOC NPs 6.06 ± 0.31 
PLGA ester-DOC-TrAb NPs 1.28 ± 0.22 
PLGA ester-DOC-ScFv NPs 0.842 ± 0.29 
PLGA acid-DOC-TrAb NPs 3.72 ± 0.14 




Figure 20. Mean in vitro IC50 for conventional docetaxel, PLGA ester-DOC, PLGA 
acid-DOC, PLGA ester-DOC-TrAb, PLGA ester-DOC-ScFv, PLGA acid-DOC-TrAb, 
and PLGA acid-DOC-ScFv in SK-BR-3 cells at 48 hours. Cell viability was evaluated 














ü Fourth Objective: To investigate the in vitro tumor cell targeting by evaluation of 
HER2 receptor expression in MCF-7 (moderately expressed HER 2 receptor) and 
SK-BR-3 (overexpressed HER2) 
 
 
5.8. Measuring HER-2 Expression  
Measuring HER2 receptor expression on the surface of breast cancer cells would 
be useful to confirm the ability of modified NPs formulations in targeting HER2 
receptors. The fluorescent anti-HER-2 Ab was used to identify the HER-2 receptors on 
the cells treated with modified NPs by flow cytometry. Untreated cells, cells treated 
with conventional Herceptin, plain NPs were utilized as control groups. The similar 
groups were tested by western blotting analysis to confirm the results from flow 
cytometry. 
 
5.8.1. Flow Cytometry 
Different formulations were used to treat both MCF-7 and SK-BR-3 cell lines 
for 48 hours to measure the amount of HER2 expression on the cell line after 
treatment. Dot plots and forward side scattering histograms were employed to measure 
the effects of treatment with different formulations. Less than 5% of the gated 





5.8.1.1. HER2 expression in SK-BR-3 cell line 
The difference between MCF-7 and SK-BR-3 is that SK-BR-3 overexpresses 
HER2 receptors. SK-BR-3 was treated with different formulations to show the 
differences in HER2 expressions which indicate the targeting ability of modified NPs 
formulations. Data are presented by depending on the type of polymer. The cells 
treated with conventional DOC, conventional Herceptin or conventional ScFv showed 
the relatively high parent fluorescence percentage (PF%) for HER2 expression 
(92.94%, 95.37, and 95.92% respectively). DOC-loaded NPs modified with both TrAb, 
or ScFv showed a significant reduction in the PF% for HER2 expression (around 86%). 
Nevertheless, modified acidic terminated NPs proved better at decreasing the PF% for 
HER2 expression in contrast to conventional medications (conventional DOC, 
conventional Herceptin, conventional ScFv or conventional combination of Herceptin 
and DOC), as shown in Figures 21 and 22.  
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Figure 21. The parent fluorescence percentage of positive cells expressing HER2 after 
treating SK-BR-3 cells with ester PLGA NPs (plain PLGA ester, PLGA ester-DOC, 
PLGA ester plain-TrAb, PLGA ester-DOC-TrAb, PLGA ester plain-ScFv, PLGA 
ester-DOC-ScFv) compared to untreated, conventional DOC, conventional ScFv, 
conventional Herceptin, combination of conventional DOC & Herceptin, after 48 
hours. The statistical significance between NPs formulations and conventional DOC is 
represented by the sign (*); the significance of NPs formulations in comparison with 
conventional anti-HER2 is presented by the sign (+). The level of significance was set 
to p < 0.05 (ANOVA followed by Pairwise multiple comparison test method). Data are 
represented as mean percentage ± SD (n=3). 
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Figure 22. The parent fluorescence percentage of positive cells expressing HER2 after 
treating SK-BR-3 cells with COOH PLGA NPs (plain PLGA COOH, PLGA COOH-
DOC, PLGA COOH plain-TrAb, PLGA COOH-DOD-TrAb, PLGA COOH plain-
ScFv, PLGA COOH-DOC-ScFv) compared to untreated, conventional DOC, 
conventional ScFv, conventional Herceptin, combination of conventional DOC & 
Herceptin after 48 hours. The statistical significance between COOH modified NPs 
formulations and conventional DOC are represented by the sign (*); the significance of 
NPs formulation combating to conventional anti-HER2 is represented by the sign (+), 
and the significance of modified NPs in comparison to the combination of conventional 
DOC & Herceptin is represented by the sign († ). The level of significance was set to p 
< 0.05 (ANOVA followed by Pairwise multiple comparison test method). Data are 







 The lowest percentage of HER2 expression appeared when the cells were 
treated with PLGA COOH-DOC-TrAb (68.06%), followed by PLGA COOH-DOC-
ScFv, where the PF% was 76.75%. Modified PLGA COOH-DOC verified a powerful 
decline in the percentage of fluorescence intensity for HER2 expression compared to 
ester-modified NPs as Figure 23 shows.  
 
 
 Figure 23. The parent fluorescence percentage of positive cells expressing HER2 after 
treating SK-BR-3 cells with both ester- and acidic-modified PLGA encapsulated DOC 
and conjugated with whole IgG and ScFv anti-HER2 NPs (PLGA ester-DOC-TrAb, 
PLGA ester-DOC-ScFv, PLGA COOH-DOC-TrAb, PLGA COOH-DOC-ScFv) after 
48 hours. The statistical significance between modified NPs formulations are 
represented by the sign (*). Data are represented as mean percentage ± SD (n=3). 
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 The percentage of median fluorescence intensity (%MFI) for HER2 expression 
was about 66% for both plain and loaded PLGA ester-TrAb, a percentage that showed 
a statistically significant difference in comparison to the combination of conventional 
DOC and Herceptin, conventional Herceptin, conventional ScFv, and conventional 
DOC (Figure 24). However, PLGA ester-DOC-ScFv did not show significant 
differences in %MFI for HER2 expression for SK-BR-3 cell line, in contrast with the 
combination of conventional DOC and Herceptin. Acidic terminated PLGA NPs 
showed the same results, whereas COOH NPs modified with whole Ab showed a 
significant reduction in %MFI for HER2 receptors, unlike the COOH NPs modified 
with ScFv as Figure 25 presents. The comparison of the %MFI for all modified NPs 





Figure 24. Relative percentage of median fluorescence intensity expressing HER2 
after treating SK-BR-3 cells with ester-PLGA NPs (plain PLGA ester, PLGA ester-
DOC, PLGA ester plain-TrAb, PLGA ester-DOC-TrAb, PLGA ester plain-ScFv, 
PLGA ester-DOC-ScFv) versus untreated, conventional DOC, conventional ScFv, 
conventional Herceptin, combination of conventional DOC & Herceptin, after 48 
hours. The statistical significance between NPs formulations and conventional DOC 
and conventional ScFv are represented by the sign (*); the significant of modified NPs 
comparing to conventional Herceptin is presented by the sign (+), and the significance 
in comparison to the combination of conventional DOC & Herceptin is indicated the 
sign († ). Data are represented as mean percentage  ± SD (n=3). 
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Figure 25. Relative percentage of positive median fluorescence intensity expressing 
HER2 after treating SK-BR-3 cells with acidic PLGA NPs (plain PLGA COOH, PLGA 
COOH-DOC, PLGA COOH plain-TrAb, PLGA COOH-DOC-TrAb, PLGA COOH 
plain-ScFv, PLGA COOH-DOC-ScFv) versus untreated, conventional DOC, 
conventional ScFv, conventional Herceptin, combination of conventional DOC & 
Herceptin, after 48 hours. The statistical significance between NPs formulations 
comparing to conventional DOC are represented by the sign (*); the significance of 
modified NPs formulation and conventional ScFv is represented by the sign (+), and 
the significance of modified NPs formulation comparing to the combination of 
conventional DOC & Herceptin and conventional Herceptin is indicated by the sign († 





Figure 26. Relative percentage of positive median fluorescence intensity expressing 
HER2 after treating SK-BR-3 cells with both ester- and acidic-modified PLGA 
encapsulated DOC and conjugated with whole IgG and ScFv anti-HER2 NPs (PLGA 
ester-DOC-TrAb, PLGA ester-DOC-ScFv, PLGA COOH-DOC-TrAb, PLGA COOH-
DOC-ScFv) after 48 hours. The statistical significance between modified NPs are 
represented by the encompassing line marked with the sign (*). The level of 
significance was set to p < 0.05 (ANOVA followed by multiple comparison test 





5.8.1.2.HER2 expression in MCF-7 cell line 
Following the same steps conducted with SK-BR-3, MCF-7 (moderately 
expresses HER2) was treated with different formulations to show the differences in 
median fluorescence intensity (MFI) of MCF-7 after staining with anti-HER2 FITC Ab 
as well as the percentage of positive cells for HER2 expression as Figure 27 represents. 
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Also, Figure 28, shows the differences in the percentage of mean fluorescence for 
HER2 expression after treating the cells for 48 hours.  
 
 
 Figure 27. The parent fluorescence percentage of positive cells expressing HER2 after 
treating MCF-7 cells with plain PLGA ester, PLGA ester-DOC, PLGA ester plain-
TrAb, and PLGA ester-DOC-TrAb compared to untreated, conventional DOC, 
conventional Herceptin, combination of conventional DOC & Herceptin, after 48 





 Figure 28. Relative percentage of positive median fluorescence intensity expressing 
HER2 after treating MCF-7 cells with plain PLGA ester, PLGA ester-DOC, PLGA 
ester plain-TrAb, and PLGA ester-DOC-TrAb versus untreated, conventional DOC, 
conventional Herceptin, combination of conventional DOC & Herceptin, after 48 




5.8.2. Western Blot 
To verify the results from flow cytometry studies, the western blot experiment 
was carried out to measure the relative HER2 protein expression levels after treating 
the SK-BR-3 cell with modified NPs formulations for both ester- and acidic- 
terminated PLGA and conventional Herceptin, conventional DOC and the conventional 
combination of DOC and Herceptin while maintaining similar conditions. Blotting 
membranes were incubated with the respective Ab against HER2 and GAPDH. Figure 
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29, shows the protein blotting bands and the relative HER2 protein expression 
percentage for both timelines presented in Figure 30. 
Conventional DOC and plain NPs showed a high level of HER2 expression for 
both timelines which was almost similar to the level of HER2 for untreated cells. This 
result was expected because there was no targeting ligand available to conjugate to the 
HER2 receptors. The data for modified NPs showed the same pattern that was 
observed by flow cytometry. There was a remarkable reduction of HER2 expression, 
especially after 48 hours of the treatment. NPs ester-DOC-ScFv had the highest 
suppression of HER2 receptors (6.2%) and NPs ester-DOC-TrAb showed about 
11.02% of HER2 expression. NPs COOH-DOC-TrAb suppressed the HER2 expression 
to 14.3%. The least reduction in HER2 expression occurred with NPs COOH-DOC-






Figure 29. Protein expression profile (15 µg) for HER2 in SK-BR-3 cells which was 
treated by the conventional Herceptin, conventional DOC, combination of conventional 
DOC & Herceptin, PLGA ester-DOC-TrAb, PLGA ester-DOC-ScFv, PLGA COOH-




Figure 30. The percentage of protein expression profile for HER2 in SK-BR-3 cells 
which was treated by the conventional Herceptin, conventional DOC, combination of 
conventional DOC & Herceptin, PLGA ester-DOC-TrAb, PLGA ester-DOC-ScFv, 
PLGA COOH-DOC-TrAb, and PLGA COOH-DOC-ScFv for two different time points 














6.1.  Yield Percentage 
Several methods are available for preparation of polymeric PLGA formulations. 
Comparing the precipitation technique and the solvent evaporation method as two 
commonly used methods for NP development; the precipitation techniques resulted in a 
low yield percentage (recovery rate). The reason for this is the low encapsulation 
efficiency of the NPs formulations prepared by the precipitation method due to the 
insufficient emulsification between the hydrophilic and hydrophobic phases (Agnihotri, 
Mallikarjuna, & Aminabhavi, 2004; Bilati, Allemann, & Doelker, 2005). Besides, 
COOH PLGA NPs formulations had a higher yield percentage than ester NPs 
formulations that had been prepared by the solvent evaporation method. Using ethyl 
acetate as the organic solvent in the formulations with COOH-terminated PLGA 
polymer gave low yield; therefore, it was critical to use chloroform as an alternate 
since, it has been commonly used in NPs preparation. When ethyl acetate was used 
with COOH-terminated PLGA, the particle size was very small, as shown in Table 12, 
which means the drug encapsulation was low, and this also explains the low yield 
(Sahana, Mittal, Bhardwaj, & Kumar, 2008; Soppimath & Aminabhavi, 2002). The 
results confirmed the superiority of the solvent evaporation technique in polymeric 






6.2. Antibody Conjugation to NPs Surface 
Many researchers endeavor different techniques to conjugating Ab to 
nanoparticles for targeting drug delivery formulation by trying different linkers because 
there is no established method yet (Arruebo et al., 2009; Montenegro et al., 2013; Yang 
et al., 2009; Yezhelyev et al., 2006). The Ab can be attached directly to the surface of 
NPs, depending on the physical adsorption. However, physical adsorption attachment 
is not entirely stable, and it might cover the binding site of the Ab. Thus, the idea of 
using linkers to conjugate the ligand is a common approach in drug targeting 
formulation research, but many factors must be considered in choosing the spacer 
(Veiseh, Gunn, & Zhang, 2010). One of the main factors is the length of the spacer 
arm, which helps to reduce the steric hindrance and improve the accessibility of the Ab 
to receptor binding sites (Khandare & Minko, 2006; Mehvar, 2000).  
In this study, two different linkers were used (BS3 or NHS/EDC) to conjugate 
TrAb, or ScFv anti-HER2 in the surface of PLGA NPs encapsulated DOC.  
Bis(sulfosuccinimidyl) (BS3) was added in the first step of NPs preparation to be 
embedded in the surface of NPs. BS3 has a reactive group (N-hydroxysulfosccinimid 
(NHS) at both ends, and it is conjugated to the ligand in a one-step reaction 
(homobifunctional) by releasing Sulpho-NHS (Figure 31). The covalent amide bond 
between the BS3 and the ligand is more stable than the physical adsorption and 
conjugation occurs at neutral pH to avoid Ab denaturation.  
Conjugation of NHS/EDC (N-hydroxysuccinimide)/ (1-ethyl-3- [3 
dimethylaminopropyl]-carbodiimide) to the PLGA NPs surface involves a 
heterobifunctional process (Figure 32). In fact, the NHS/EDC linker was the reason 
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behind using COOH-terminated PLGA because carboxylic acid was needed to 
conjugate to EDC. The COOH forms an unstable reactive acylisourea ester with EDC 
and subsequent addition of NHS results in a semi-stable amine that conjugates to the 
Ab directly by forming the amide bond. FTIR confirmed the formation of amide bond 
between linkers (BS3 or NHS/EDC) and antibodies (TrAb or ScFv). However, because 
the amide bond is distinctive character to the compound-containing protein, the FTIR 
spectrum of modified and unmodified NPs needed to be compared to emphasize the 
difference. The presence of the amide bond between BS3 linker and NPs showed in 
Figure 7, and Figure 8 for the NHS/EDC linker. The central peak for PLGA appeared 
in 1750 cm-1, and the amide bond vibrates in ~1640 cm-1 confirming the attachment of 
the Ab (Fu, Griebenow, Hsieh, Klibanov, & Langer, 1999; Ya-Ping Li, 2001).  
 
 
Figure 31. Schematic reaction to show the conjugation between the spacer (BS3) and 
the ligand in ester PLGA polymeric nanoparticles. The BS3 linker embeds on the NPs 
surface to form a covalent bond between the BS3 and ligand. This method can be 
applicable for both ester-and acidic-terminated PLGA nanoparticles
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Figure 32. Schematic reaction to show the conjugation between the spacer (N-
hydroxysuccinimide)/ (1-ethyl-3- [3 dimethylaminopropyl]-carbodiimide) and the 
ligand in COOH-terminated PLGA polymeric nanoparticles, using a EDC/NHS spacer 
with COOH-terminated PLGA only. The ligand attaches to the nanoparticle by forming 
a covalent amide bond after confirming the intermediate compounds (acylisourea ester 

















6.3. Physicochemical Properties (Size, ZP, and PDI) 
One of the most critical factors in targeting drug delivery formulations is 
internalizing the therapeutic agent into the specific cells. The size, ZP, shape, and the 
surface chemistry of the NPs significantly impact cellular uptake as well as 
biodistribution and pharmacokinetics of the formulations (De Jong & Borm, 2008; 
Veiseh et al., 2010). However, the aggregation and agglomeration, chemical 
composition, and NPs protein interaction play an essential role in the cellular uptake 
mechanism (Oh & Park, 2014; C. Sun, Lee, & Zhang, 2008). There are different 
pattern endocytosis cellular uptake (pinocytosis or phagocytosis) depending on the size 
of the particles (J. Wang, Byrne, Napier, & DeSimone, 2011; Zhao et al., 2011). 
During nanoparticle development, our initial focus was NPs size because large 
NPs would be filtered via the reticuloendothelial system specifically by phagocytosis, 
which would result in unfavorable biodistribution and pharmacokinetic characteristics 
of the formulation (Albanese, Tang, & Chan, 2012; Jiang, Kim, Rutka, & Chan, 2008). 
Solid tumors have vascular pores around 400–600 nm and high interstitial pressure at 
the center of the tumor site, which can increase retention time because of reduction in 
blood flow. Therefore, NPs formulations in this size range (400–600 nm) could take 
advantage of the permeability and retention effect (Adiseshaiah, Hall, & McNeil, 
2010). Also, an anti-HER2 Ab attached on the surface of NPs would actively target the 
NPs to the tumor tissue (Cho, Wang, Nie, Chen, & Shin, 2008; Danhier, Feron, & 
Preat, 2010). NPs around 500 nm would be internalized through receptor-mediated 
endocytosis (Ding & Ma, 2012; Vacha, Martinez-Veracoechea, & Frenkel, 2011).  
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Another important factor is the surface charge of the NPs (ZP). Low ZP 
prolongs the formulation’s circulating time in blood to reach and accumulate in the 
tumor. On the other hand, having a positive charge on the surface helps electrostatic 
interaction with the negative charge on the cell surface; however, the formulation 
would end up with nonspecific internalization (Frohlich, 2012; He, Hu, Yin, Tang, & 
Yin, 2010). Also, freeze-drying (FD) is one of the challenges in this research; all NPs 
formulations sizes and PDI increased after FD, which could be due to the aggregation 
stress on the particles during FD or to the disruption of electrostatic repulsion between 
particles (Holzer et al., 2009). The high aggregation tendency led to a large PDI, so the 
highest value of the PDI is 1, which means that the formulation has a wide range of 
size distribution. Moreover, the ZP showed a trend toward more negative values after 
FD. Therefore, different amounts of cryoprotectant (sucrose) (0.1%, 0.16%, 0.33%, 
0.5%, 0.66%, 0.83%, 1%, and 1.16%) were added as a steric stabilizer to avoid the 
attraction between NPs to prevent the aggregation and coagulation. The effect of 
cryoprotectant decreased the particle size and PDI for NPs, when 1.7 mg/ml of sucrose 
used, the mean size of PLGA ester-DOC-BS3 was 257.2 ± 15.77 nm and 329.8 ± 9.39 
nm for PLGA COOH-DOC (Table 10 and 12). The ZP rate was also found to be less 
negative after using sucrose. 
DOC addition also led to lowering the particle size; during NPs preparation, 
there was would be an interaction between the polymer and the drug that could 
condense the droplet in the emulsion, leading to smaller particle sizes. After the Ab 
attachment, there was an increase in NPs size, and ZP shifted towards more positive or 
neutral; however, no change was noted in the PDI. Interestingly, there was no 
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significant difference in the size when the whole anti-HER2 (TrAb) was attached to the 
surface in comparison to the fragment Ab (ScFv) (Table 13). Finally, four NPs 
formulations were chosen for further analysis because its potential of targeting and 
delivering DOC depending on their physicochemical characterizations; PLGA ester-
terminated polymer encapsulate DOC with 1.7 mg/ml sucrose decorated with 300 µg of 
TrAb or Scfv by BS3 spacer, and PLGA COOH-terminated polymer encapsulated 

















6.4. Surface Morphology 
The shape of the particles affects the cellular uptake; therefore, both transmission 
electron microscopy (TEM) and scanning electron microscope (SEM) were used to 
study the morphology of NPs formulations. SEM and TEM images confirmed the 
uniform spherical shape for all formulations. Spherical particles have better uptake than 
other shapes because of the small angle (acute ~ 45o) between the surface of the cells 
and the NPs (Arkan, Saber, Karimi, & Shamsipur, 2015; Florez et al., 2012). The large 
angle on top of the cells means particles would be spread on the surface, negatively 
affecting internalization. Chromium and gold are used to coat the formulations in SEM 
imaging to prevent the direct contact between the beam and NPs. Conjugating the Ab 
on the surface of polymeric NPs did not change the morphology of NP. Both 
microscopes gave smaller diameters of NPs in comparison to the Zetasizer size because 
of the differences in the measuring techniques. In the microscope, the samples are 
present in dry form; besides, it usually images a single particle. In contrast, in the 
Zetasizer, the samples are dispersed in the aqueous phase, and DLS gives the average 
size (Bootz, Vogel, Schubert, & Kreuter, 2004; Chattopadhyay et al., 2012; Ito, Sun, 











6.5. Drug-Loading Quantification for Docetaxel 
Compared to previous work in our lab, the amount of DOC loaded per mg of NPs 
improved significantly (about 3-fold) for PLGA ester-BS3-TrAb NPs formulation 
(from 7.13 ± 0.89 µg per mg of NPs to 21.78 ± 3.34 µg per mg of NPs). This may be 
due to enhanced sonication time, amplitude and temperature which encourages uniform 
mixing with higher drug loading. One of the important factors in NP preparation is 
maintaining the cold temperature in all steps of NPs preparation to keep the particle 
from denaturing, especially because both sonication and centrifugation produce heat. 
Unmodified acidic-terminated PLGA NPs had higher loading compared to ester-
formulations, but the differences in the amount of DOC loading was not statistically 
significant. However, with modified NPs with TrAb for COOH NP, the loading of 
DOC was found to be higher than ester-modified NPs, which could be attributed to the 
presence of BS3 (hydrophilic) in the surface of NPs that caused more drug loss in the 
Ab attachment step. 
 The DOC encapsulation efficiency depends directly on the initial amount of 
DOC, PLGA, and sucrose added in the first step of NPs preparation. Another 
difference in the formulations compared to previous work is that the amount of sucrose 
significantly decreased from 10% to 0.5%, which gave us 15 % and 45 % entrapment 
of DOC, respectively. Overall, there was a significant improvement in DOC loading 
compared to similar preparation techniques were done by Musumeci et al., 2006 and 
Youm et al., 2011 lab. 
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6.6. Antibody Loading Quantification 
As discussed before, there is no well-established method to attach the ligand 
with polymeric NPs efficiently while maintaining the efficiency of the medications. 
Therefore, in this research, both BS3 or NHS/EDC were used to examine the 
capability. Hence, quantitation of protein by the BCA assay supported the notion that 
conjugation was successful. Based on previous work in our lab, there is no significant 
increase in the amount of Ab conjugation when increasing the amount of the linker 
(Sadat, 2015). However, after using different amounts of trastuzumab to attach to NPs, 
we found that the higher amount of Ab initially used provided a higher amount of 
attached Ab; 300 µg of Ab gave the highest amount of Ab attachment as well as a 
higher attachment efficiency percentage. 
 Initially, indirect quantification was obtained by measuring the remainder of 
the unconjugated Ab in the washing solvent. There was a significant improvement in 
the amount of Ab attached to the ester-terminated nanoparticles compared to prior 
work in our lab, from around 12.05 ± 1.39 Bg/mg to 22.8 ± 3.78 Bg/mg for modified 
ester-terminated PLGA NPs with TrAb. The detection of the fragment ScFv and low 
quantity TrAb was zero, which meant 100% attachment, as presented in Tables 16 to 
23, which was a big concern for the efficiency of indirect quantification. Consequently, 
Ab conjugation was determined by measuring how much Ab attached to the surface of 
NPs after FD directly (Table 20). The modified COOH-terminated PLGA with TrAb 
had the highest amount of Ab incorporated at 16.33 ± 2.69 µg/mg of NPs, which could 
be attributed to the smaller size and larger surface area. Conversely, there was no 
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significant difference in the amount of ScFv anti-HER2 attached to both ester- and 
COOH-modified NPs.  
In conclusion, having the Ab on the surface of NPs increases the hydrophilicity, 
and positive charge of NPs. Also, the modified NPs would improve the specific 
targeting and, the uptake of the tumor overexpresses HER2 receptors. The conjugation 
of TrAb was higher in comparison with the fragment anti-HER2 (ScFv), though the 


































6.7. Evaluation of In Vitro Release Pattern of Docetaxel from Modified NPs   
Ester-modified PLGA NPs with TrAb was conducted in both pH 7.4 and pH 5 for 
120 hours. Early burst release phenomena showed a higher release in the presence of 
acidic pH. This could be attributed to the presence of DOC on the surface or close to 
the surface of NPs, which would release faster. Also, the faster release at the lower pH 
value could be due to the re-protonation of the amino group of DOC. Although, having 
the TrAb conjugating on the surface of NPs increased the hydrophilicity, which 
enhanced the rate of erosion and/or diffusion of the polymer. Then, DOC continued 
diffusion through the polymeric matrix, which is referred to as control release. This 
concept of burst release could help to suppress the growth of a tumor as an immediate 
action, whereas the maintaining effect comes from the control release of chemotherapy 
(Avgoustakis et al., 2002; Mittal, Sahana, Bhardwaj, & Ravi Kumar, 2007; Z. Zhang & 
Feng, 2006). 
Another remarkable phenomenon is having a higher release of DOC in acidic 
media compared to neutral pH. A tumor has an acidic environment, so the release of 
DOC would be more specific in the tumor area compared to other organs or in the 
circulation, where the pH is neutral. That would help in minimizing the side effects of 








6.8. Cell Cytotoxicity  
Modified and unmodified formulations were tested in SK-BR-3 cell line to 
measure the cancer cell viability (or cancer cell mortality) against the recently used 
medications (DOC and Herceptin). Because the new formulations have ester- and 
acidic- terminated PLGA as a carrier, a cytotoxicity study is needed to confirm that 
there was no toxicity influence for PLGA in general except in when a high 
concentration was used. This toxicity could be caused by to having a high quantity of 
NPs, which would change the pH and the viscosity of the media, leading to cell death 
as shown in Figure 15.  
The same concentration of DOC was used to compare the cell viability for the 
modified formulations with each other and with conventional DOC, Herceptin, and the 
combination of DOC and Herceptin. Overall, a more significant cytotoxicity (cancers 
toxicity) effect was observed when the DOC concentration was increased. In the case 
of ester PLGA formulations, the NPs conjugated with TrAb, showed an excellent result 
(cancers toxicity) in at low concentrations, when compared with NP ester-DOC-ScFv. 
However, by increasing the concentration of both NPs formulations (ester-DOC-TrAb 
and ester-DOC-ScFv) the cytotoxicity effect was almost equal. Both TrAb and ScFv 
anti-HER2 modified ester NPs formulations showed significant synergistic anticancer 
activity compared to the current clinical dosage form. This enhancement in cytotoxicity 
can be attributed to the effect of Ab in targeting and enhancing the cellular uptake via 
HER2 receptor-mediated endocytosis. 
For acidic-terminated PLGA formulations, NPs conjugated to TrAb showed 
higher tumor cell cytotoxicity than ScFv. COOH PLGA-DOC-TrAb had a higher and 
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significant cytotoxic effect than a combination of conventional DOC and Herceptin 
treatment. TrAb might be more bioactive, so NPs had a higher level of interaction with 
the cell. However, the cell viability for COOH PLGA-DOC-ScFv formulations was not 
low. These data suggested that the targeting and uptake were not that effective, which 
could be attributed to performing the attachment in acidic pH (5 pH). The acidic 
environment might denature the fragment Ab (Calmettes, 1991; Vermeer & Norde, 
2000; Welfle, Misselwitz, Hausdorf, Hohne, & Welfle, 1999). Also, the TrAb might 
have had a better effect than the fragment anti-HER2 because, according to the 
literature, the density of the Ab is more critical in drug targeting and uptake (Holliger 
& Hudson, 2005). In addition, the fragment Ab has only one binding site, whereas the 
TrAb can conjugate to the receptors by two binding epitopes.  
By comparing the modified formulations to each other, it can be concluded that 
both ester-modified PLGA formulations (TrAb or ScFv) were able to induce cell death 
more than COOH PLGA-modified formulations. Thus, the Ab in the ester formulation 
was more biologically effective for directing the HER2 receptor and probably 
internalizing the cell via receptor-mediated endocytosis. Another reason could be that 
the BS3 gave a more accessible spacer arm, which improves the targeting and the 
delivery as well as the cytotoxicity. Also, to perform the attachment via NHS/EDC 
requires acidic pH, which might denature or inactivate the Ab, reducing the targeting 
and the toxicity.  
For quantitative analysis for the formulations, IC50 was performed to result in the 
drug concentration that killed 50% of the cells at the designated time. The IC50 can be 
ranked according to the killing efficiency as follows: ester PLGA-DOC-ScFv > ester 
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PLGA-DOC-TrAb > COOH PLGA-DOC-ScFv > COOH PLGA-DOC-TrAb. 
Fragment Ab showed better IC50 values versus TrAb, which could be because the 
penetration of the fragment Ab takes only 16 hours. However, the penetration of the 
entire IgG Ab takes 54 hours (Hudson & Souriau, 2003). Therefore, the recycling of 
the HER2 receptor would be faster in the cells treated with fragment formulations, 




















6.9. Measuring HER2 Expression  
All the cell lines were used to evaluate the expression of HER2 receptor on the 
surface of the cells. The incubation time for the treatments was 48 hours based on prior 
work in our lab. The data presented by focusing on the %PF, which refers to the 
fluorescence percentage of the receptors that stained all cells, and similarly the 
percentage of median fluorescence (%MFI) demonstrates the percent of the receptors 
stained per one cell. For the MCF-7 cell line, there was no significant difference in 
either the %PF or %MFI while treating the cells with different formulations. This was 
expected because the expression of HER2 receptors is low to moderate in the MCF-7 
cell line. 
For SK-BR-3 cells, all modified ester formulations showed a significant 
reduction in the %PF compared to the cells treated with conventional Herceptin and 
untreated as well, and there was no significant difference between the fragment and 
whole Ab in ester-modified NPs. Also, acidic-modified PLGA NPs with ScFv had a 
significant reduction of %PF; however, the COOH PLGA-DOC-TrAb yielded the 
highest reduction in %PF (68%). Additionally, all formulations showed a significant 
reduction in the %MFI, except for COOH PLGA-DOC-ScFv NPs whereas the %MFI 
was 86.1%. Remarkably, the %MFI was higher in untreated cells than in the cells 
treated with conventional ScFv and plain NPs, which could be because more HER2 
receptors were produced in surviving cells. Overall, all NPs formulations showed an 




HER2 expression in SK-BR-3 cell line after different treatments was evaluated 
by Western blot analysis. Overall there was an obvious reduction in HER2 expression 
for the cells treated with modified NPs which confirmed the capability of delivering 
and targeting HER2 receptors.  There was limited reduction in HER2 expressions when 
the cells were treated with plain NPs, that could be attributed to the electrostatic 
interaction between the plain NPs that had negative ZP and HER2 receptors which is 

















7. CONCLUSION  
Chemotherapeutics are currently the most effective treatments for cancer patients; 
however, most chemotherapy has many side effects that can adversely affect other 
organs due to its inability to target tumor cells. Therefore, this study is focused on 
preparing modified PLGA nanoparticles with a chemotherapeutic agent (DOC) and 
attaching TrAb or the fragment ScFv anti-HER2 to the surface of the NPs as a ligand to 
target HER2 expressing breast tumor cells. This process would enhance the targeting 
properties of the treatment and improve chemotherapeutic residence time and 
distribution to tumor. Nanoparticles are used in novel drug delivery systems to control 
and target therapeutic agents to the disease site.  
One of the vital factors in the NPs’ preparation is size. Taking into consideration 
the advantages of the tumor microvasculature with a pore size between 400 nm and 600 
nm, NPs of similar size may accumulate in the tumor site (Ding & Ma, 2012). Many 
studies have confirmed the ability for intracellular uptake with NPs that have a 
diameter of less than 500 nm (Vacha et al., 2011). Because FD is an essential step in 
NPs preparation and there is a significant increase in NPs’ size after FD, a different 
quantity of cryoprotectant was used to decrease stress and aggregation during FD. 
Technically, a cryoprotectant, or sucrose specifically, minimizes the hyperosmotic 
effect and stabilizes both the steric and electrostatic hindrance, which prevents 
aggregation as well as crystallization.  
The second focus was on the ZP of NPs, where the FD induced a more negative 
surface charge. DOC and PVA residues also demonstrated a negative charge. PVA was 
essential for maintaining the interfacial tension between the particles and to uniformly 
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distribute small NPs. The presence of sucrose helped decrease the negative ZP. Almost 
all the modified formulations in this study had neutral ZP, which helped reduce the 
phagocytic rate and increased the NPs’ circulation time so it could reach the tumor site. 
Besides, neutral ZP prevents nonspecific electrostatic binding. In addition, having high 
negative ZP made the formulation pharmaceutically unstable as well as decreased 
cellular uptake because of phagocytosis. Both TrAb and ScFv modified the NPs’ 
required size (>400 nm) with uniform PDI and neutral ZP, which was achieved for all 
formulations. 
A surface morphology analysis assured the spherical shape of NPs and affirmed 
that an Ab conjugation did not change the NPs shape. Having spherical NPs helped the 
NPs’ uptake due to the small, acute angle between the cell surface and the particles.  
The DOC loading efficiency improved significantly and reached 85% for the 
TrAb-modified COOH-PLGA NPs and around 70% for TrAb-modified ester-PLGA 
NPs. BS3 and NHS/EDC cross-linking agents were used to conjugate Ab to the surface 
of the NPs by covalent conjugation. There was no prominent or significant difference 
in the amount of Ab attached to the NPs surface.  
NPs loaded with DOC and modified with TrAb had burst release at first where 
50% of the DOC was released in the first 24 hours in acidic pH, which could instantly 
help suppress a tumor’s growth. Then DOC had a controlled release to continue the 
effect. The release was affected by the pH; therefore, in an acidic medium, the rate of 
release would be higher than in a neutral pH. This pH-dependent phenomenon would 
be beneficial in tumor-targeting the drug delivery because tumors have an acidic 
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environment where the DOC can be released in the tumor site, thus minimizing 
systemic toxicity. 
The percentage of cell viability and the cytotoxicity that quantitatively resulted 
in 50% growth inhibition (IC50) were analyzed to evaluate the chemotherapeutic 
response for conventional drug and all modified PLGA NPs. Cell viability was higher 
with cells treated with conventional DOC and with a combination of conventional 
DOC and Herceptin compared to ester NPs modified with either TrAb or ScFv. In 
addition, the acidic modified NPs showed high cytotoxicity. Modified PLGA ester 
exhibited the lowest IC50 (the highest cytotoxicity) followed by modified PLGA acidic-
DOC-ScFv when compared to the PLGA acidic-DOC-TrAb. This result suggests the 
enhancement of cytotoxicity that might be related to the active cellular uptake mediated 
by targeting HER2 receptors, which then increased the intracellular concentration of 
DOC. 
All the modified NPs formulations confirmed their ability to target HER2 
receptors and deliver chemotherapy (DOC) by measuring the level of HER2 
expression. The results from flow cytometry showed the reduction in HER2 expression 
for all the cells treated with modified NPs. Remarkably, both ester- and acidic- PLGA 
encapsulated with DOC and modified with TrAb were found to be more prominent in 
targeting HER2 receptors when compared to fragment-modified NPs. A western blot 
analysis affirmed that all modified NPs formulations had the ability to target HER2 
receptors, which therefore decreased HER2 expression. 
To conclude, there is the potential that all anti-HER2-modified PLGA NPs 
formulations can target drug delivery to HER2 overexpressing breast cancer. Thus, 
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ligand-modified, structurally concealed PLGA NPs could be a promising delivery tool 
for targeting HER2 breast tumors in vivo to improve the therapeutic effects of 






















8. FUTURE DIRECTION  
The present work was an attempt to improve the drug loading of PLGA NPs 
encapsulated DOC that was modified with anti-HER2 ligands to target and deliver the 
DOC to HER2 overexpressing breast cancer. This research can be advanced by further 
investigating different objectives. The following recommendations and future 
directions should be considered:  
1. Acidic terminated PLGA could be used with the BS3 cross-linker to 
conjugate the anti-HER2 on the surface of NPs were the NPs could better 
load the chemotherapy as well as the ligand, which would improve the 
physiochemical properties and the efficacy of the NPs.  
2. A smaller recombined Ab like Fab or Fab2 could work better than ScFv. 
First, the spacer arm could be longer due to the attachment of the Fab to 
the variable region and this might help the accessibility of Ab in 
conjugating the epitope of the antigen (receptors). Second, there would be 
two antigens’ bonding sites instead of one, as is the case of ScFv.  
3. The MDA-MB-453 and BT-474 cell lines could be used to confirm the 
targeted drug delivery of all formulations by measuring the HER2 
expressions. Furthermore, this test would help in animal modeling for 
future in-vivo experiments. 
4. Subcellular localization could examine the location of the protein in a cell, 
which would assist in investigating the intracellular Ab pathway. 
5. Cell cycle and apoptosis assays could also help investigate the antitumor 
mechanism of DOC loaded in PLGA NPs. 
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6. Investigate the down regulation pathways for further direction of anti-
HER-2 mechanism of action. 
7. In vivo studies such as the following could evaluate the effects of the 
targeted delivery systems for breast cancer, overexposing HER2 receptors: 
A. A pharmacokinetics study to measure the DOC concentration in the 
plasma.  
B. Tumor-targeting assays, modified PLGA NPs formulations could 
encapsulate infrared dye (DiR) instead of DOC; then, injecting the 
florescent formulations into a xenograft animal model so its organs 
that could be imaged to investigate the targeting ability of modified 
NPs formulations. 
C. Antitumor assays with all modified NPs formulations injected into 
a xenograft animal model and the weight and volume of the tumor 
calculated to investigate whether the tumor had shrunk after 
treatment with modified NPs formulations. 
8. Optimization of modified NPs formulations could be useful after 
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